var title_f3_57_3984="Tetralogy Fallot RV angiogram";
var content_f3_57_3984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right ventricular angiogram in tetralogy of fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right ventricular (RV) angiogram in a patient with tetralogy of Fallot was obtained with the camera angled cranially and in a slight left anterior oblique projection. The subvalvar (*) obstruction is so severe that with systole there is absence of contrast in the RV outflow tract. The pulmonary valve annulus is small with a thickened valve. There is a small ridge of supravalvar narrowing (black arrow) and mild proximal left pulmonary artery (LPA) stenosis (red arrow).",
"    <div class=\"footnotes\">",
"     MPA: main pulmonary artery; RPA: right pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3984=[""].join("\n");
var outline_f3_57_3984=null;
var title_f3_57_3985="Etozolin: International drug information";
var content_f3_57_3985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etozolin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diuzolin (ES);",
"     </li>",
"     <li>",
"      Elkapin (AT, CZ, DE, ES, IT);",
"     </li>",
"     <li>",
"      Etopinil (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Loop",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of edema and hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Doses of 200 mg/day have been reported",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 200 mg, 400 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10382 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3985=[""].join("\n");
var outline_f3_57_3985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304131\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978822\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978825\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978821\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821167\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978824\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3986="Patient information: Friedreich ataxia (The Basics)";
var content_f3_57_3986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83432\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/46/14053\">",
"         Heart with hypertrophic cardiomyopathy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/28/35266\">",
"         Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/26/36259\">",
"         Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Friedreich ataxia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/friedreich-ataxia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H96547444\">",
"      <span class=\"h1\">",
"       What is Friedreich ataxia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Friedreich ataxia is a rare disease that damages the brain, spinal cord, and other nerves. It causes movement problems. &ldquo;Ataxia&rdquo; is the word doctors use for problems with muscle control.",
"     </p>",
"     <p>",
"      Friedreich ataxia also damages the heart and other organs. It is a serious disease that gets worse over time. It almost always runs in families. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96547459\">",
"      <span class=\"h1\">",
"       What are the symptoms of Friedreich ataxia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of Friedreich ataxia often come on slowly. Over many years, initial symptoms can get worse and new symptoms can happen. &nbsp;",
"     </p>",
"     <p>",
"      When they happen, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with arms and legs &ndash; A person with Friedreich ataxia might: &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Not being able to move the arms and legs the way he or she wants to",
"       </li>",
"       <li>",
"        Stumble or walk unsteadily",
"       </li>",
"       <li>",
"        Have trouble feeling where the feet are on the floor",
"       </li>",
"       <li>",
"        Have twitching or shaking legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eye problems &ndash; These can happen if Friedreich ataxia affects the main nerve in the eye, called the &ldquo;optic nerve.&rdquo;",
"       </li>",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        Loss of bladder control",
"       </li>",
"       <li>",
"        Foot problems, such as very high arches and bent toes",
"       </li>",
"       <li>",
"        Scoliosis &ndash; This is a spine that curves sideways, like the letter &ldquo;C.&rdquo; The spine also twists so 1 side of the back sticks up more than the other.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Friedreich ataxia usually causes a heart condition called &ldquo;hypertrophic cardiomyopathy.&rdquo; This condition causes the muscle in the heart to get too bulky (",
"      <a class=\"graphic graphic_figure graphicRef50899 \" href=\"UTD.htm?13/46/14053\">",
"       figure 1",
"      </a>",
"      ). The heart has trouble pumping blood as well as it should.",
"     </p>",
"     <p>",
"      Some people with Friedreich ataxia get type 1 diabetes (sometimes called type 1 &ldquo;diabetes mellitus&rdquo;). This is a disease that changes the way your body uses sugar.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96547474\">",
"      <span class=\"h1\">",
"       Is there a test for Friedreich ataxia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes and no. The doctor might be able to tell if you have it by learning about your symptoms and doing an exam. But because the symptoms can come on slowly, the doctor might not know right away if you have it. You should tell your doctor if anyone in your family has Friedreich ataxia.",
"     </p>",
"     <p>",
"      If the doctor thinks you might have Friedreich ataxia, he or she can order a blood test to check your genes. Most people with Friedreich ataxia have an abnormal gene, but not everyone does.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96547489\">",
"      <span class=\"h1\">",
"       How is Friedreich ataxia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for Friedreich ataxia, but doctors can treat the symptoms. Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Regular checkups with doctors who treat nerve and muscle problems, heart problems, and diabetes &ndash; A person with Friedreich ataxia will usually see many different doctors for checkups and tests. &nbsp;",
"       </li>",
"       <li>",
"        Physical and occupational therapy &ndash; These can help with balance and movement problems and doing daily activities.",
"       </li>",
"       <li>",
"        Devices that help with walking and daily activities &ndash; These include a wheelchair, walker, or other devices.",
"       </li>",
"       <li>",
"        Counseling &ndash; Talking with a counselor can help a person with Friedreich ataxia cope with a disease that gets worse over time.",
"       </li>",
"       <li>",
"        Genetic counseling &ndash; This can help explain how the disease runs in families.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96547504\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/57/3986?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83432 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-82E6EA8F2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3986=[""].join("\n");
var outline_f3_57_3986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96547444\">",
"      What is Friedreich ataxia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96547459\">",
"      What are the symptoms of Friedreich ataxia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96547474\">",
"      Is there a test for Friedreich ataxia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96547489\">",
"      How is Friedreich ataxia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96547504\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/46/14053\">",
"      Heart with hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3987="Pleural hematoma I CT";
var content_f3_57_3987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large pleural hematoma after trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan performed without intravenous injection of contrast material shows inhomogeneous opacification of the right hemithorax with mostly higher attenuation material. A right-sided chest tube is in place. Cardiomediastinal shift to the left is seen. The interventricular cardiac septum is seen as a higher attenuation structure when compared to the interventricular blood. This suggests a severe dilutional anemia due to severe hemorrhage with a hemoglobin level of less than 7 g/dL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3987=[""].join("\n");
var outline_f3_57_3987=null;
var title_f3_57_3988="Tracheal diverticul CXR CT";
var content_f3_57_3988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Chest radiograph and CT scan of a tracheal diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Chest radiograph displays a large right-sided rounded lucency at the base of the neck above the thoracic inlet. B) The CT scan confirms the nature of the lucency. It has the typical features of a tracheal diverticulum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3988=[""].join("\n");
var outline_f3_57_3988=null;
var title_f3_57_3989="Methenamine: Drug information";
var content_f3_57_3989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methenamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/26/23972?source=see_link\">",
"    see \"Methenamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/54/41827?source=see_link\">",
"    see \"Methenamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hiprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dehydral&reg;;",
"     </li>",
"     <li>",
"      Hiprex&reg;;",
"     </li>",
"     <li>",
"      Mandelamine&reg;;",
"     </li>",
"     <li>",
"      Urasal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Hippurate:",
"     </i>",
"     1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Mandelate:",
"     </i>",
"     1 g 4 times/day after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/54/41827?source=see_link\">",
"      see \"Methenamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;2-6 years:",
"     <i>",
"      Mandelate:",
"     </i>",
"     50-75 mg/kg/day in 3-4 doses or 0.25 g/30 lb 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hippurate:",
"     </i>",
"     0.5-1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mandelate:",
"     </i>",
"     50-75 mg/kg/day in 3-4 doses or 0.5 g 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F194210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hippurate: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hiprex&reg;: 1 g [scored; contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mandelate: 500 mg, 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in effect.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis or suppression of recurrent urinary tract infections; urinary tract discomfort secondary to hypermotility",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hiprex&reg; may be confused with Mirapex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methenamine may be confused with mesalamine, methazolamide, methionine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex may be confused with Eurax&reg;, Serax",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex: Brand name for methenamine [U.S. (discontinued)], but also the brand name for furosemide [Australia, China, Turkey]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex [U.S. (discontinued)] may be confused with Eurax brand name for crotamitin [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     &lt;4%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (reversible; rare), AST increased (reversible; rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Large doses (higher than recommended) have resulted in bladder irritation, frequent/painful micturition, albuminuria, and hematuria.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methenamine or any component of the formulation; severe dehydration, renal insufficiency, severe hepatic insufficiency; concurrent treatment with sulfonamides",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Use with caution in patients with gout.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reversible increases in LFTs have occurred during therapy especially in patients with hepatic dysfunction. Contraindicated in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Hiprex&reg; contains tartrazine dye, which may cause allergic reactions in certain individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used to treat infections outside of the lower urinary tract; doses of 8 g/day for 3-4 weeks may cause bladder irritation. Use care to maintain an acid pH of the urine, especially when treating infections due to urea splitting organisms (eg,",
"     <i>",
"      Proteus",
"     </i>",
"     and strains of",
"     <i>",
"      Pseudomonas",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: Methenamine may enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F194200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Foods/diets which alkalinize urine (pH &gt;5.5) decrease therapeutic effect of methenamine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (methenamine mandelate) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methenamine hippurate did not cause adverse fetal effects in animals; animal reproduction studies have not been conducted with methenamine mandelate. Methenamine crosses the placenta and distributes to amniotic fluid. Adverse fetal effects were not observed in two human trials. Methenamine use has been shown to interfere with urine estriol concentrations if measured via acid hydrolysis. Use of enzyme hydrolysis prevents this lab interference.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F194192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of methenamine are secreted in human milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F194193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foods/diets which alkalinize urine pH &gt;5.5 decrease activity of methenamine; cranberry juice can be used to acidify urine and increase activity of methenamine. Hiprex&reg; contains tartrazine dye.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hiprex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $313.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methenamine Hippurate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $209.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methenamine Mandelate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 g (100): $88.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $165.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Urex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $232.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F194180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, periodic liver function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antihydral (CH, LU);",
"     </li>",
"     <li>",
"      Haiprex (DK);",
"     </li>",
"     <li>",
"      Hexamandin (PL);",
"     </li>",
"     <li>",
"      Hipeksal (FI);",
"     </li>",
"     <li>",
"      Hiprex (AE, AT, AU, BB, BF, BJ, BM, BS, BZ, CI, CR, DO, ET, FI, GB, GH, GM, GN, GT, GY, HN, JM, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NO, NZ, OM, PA, PH, SC, SD, SE, SL, SN, SR, SV, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Mandehexan (PL);",
"     </li>",
"     <li>",
"      Mandelamine (PL);",
"     </li>",
"     <li>",
"      Mandepiril-S (MX);",
"     </li>",
"     <li>",
"      Pedipur (PL);",
"     </li>",
"     <li>",
"      Reflux (NL);",
"     </li>",
"     <li>",
"      Stoppot (PL);",
"     </li>",
"     <li>",
"      Urotractan (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methenamine is hydrolyzed to formaldehyde and ammonia in acidic urine; formaldehyde has nonspecific bactericidal action. Other components, hippuric acid or mandelic acid, aid in maintaining urine acidity and may aid in suppressing bacteria.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Gastric juices: Hydrolyze 10% to 30% unless protected via enteric coating; Hepatic: ~10% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% as unchanged drug) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allgen LG, Holmberg G, Persson B, et al, &ldquo;Biological Fate of Methenamine in Man. Absorption, Renal Excretion and Passage to Umbilical Cord Blood, Amniotic Fluid and Breast Milk,&rdquo;",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 1979, 58(3):287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/57/3989/abstract-text/484222/pubmed\" id=\"484222\" target=\"_blank\">",
"        484222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlstrom K and Lunell NO, &ldquo;Interference of Antiseptics Containing Hexamethylene Tetraamine (Hiprex&reg;) With the Estimation of Urinary Oestriol Excretion During Pregnancy,&rdquo;",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 1975, 54(4):387-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/57/3989/abstract-text/1199707/pubmed\" id=\"1199707\" target=\"_blank\">",
"        1199707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kivinen S and Tuimala R, &ldquo;Decreased Urinary Oestriol Concentrations in Pregnant Women During Hexamine Hippurate Treatment,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1977, 2(6088):682.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Safety of Antimicrobial Drugs in Pregnancy,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1987, 29(743):61-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/57/3989/abstract-text/3587115/pubmed\" id=\"3587115\" target=\"_blank\">",
"        3587115",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vainrub B and Musher DM, &ldquo;Lack of Effect of Methenamine in Suppression of, or Prophylaxis Against, Chronic Urinary Tract Infection,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1977, 12:625-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/57/3989/abstract-text/921259/pubmed\" id=\"921259\" target=\"_blank\">",
"        921259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9626 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3989=[""].join("\n");
var outline_f3_57_3989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194205\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194227\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194208\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194220\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194209\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194210\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194182\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194166\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803168\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194184\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194234\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194225\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194187\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194170\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299683\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194175\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194200\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194178\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194191\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194214\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194192\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194193\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194190\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194180\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194194\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194169\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194186\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9626\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9626|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/26/23972?source=related_link\">",
"      Methenamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/54/41827?source=related_link\">",
"      Methenamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3990="Hallux valgus anatomy";
var content_f3_57_3990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Anatomy relevant to hallux valgus deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3990=[""].join("\n");
var outline_f3_57_3990=null;
var title_f3_57_3991="Primary (congenital) encephalocele";
var content_f3_57_3991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary (congenital) encephalocele",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Tadanori Tomita, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Hideki Ogiwara, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3991/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/57/3991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3459289\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An encephalocele is a protrusion of the brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meninges through a defect in the skull (cranium bifidum) that is &ldquo;closed&rdquo; or covered with skin. Encephalocele is one of the three most common neural tube defects (NTDs). The epidemiology, clinical features, diagnosis, and management of encephaloceles are discussed in this topic review.",
"   </p>",
"   <p>",
"    The other main types of NTDs are anencephaly and myelomeningocele, which are discussed in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anencephaly, which is an open NTD as the affected region of the cranial neural tube is exposed to the body surface. It is a severe defect, and is not compatible with survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11237?source=see_link\">",
"       \"Anencephaly\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myelomeningocele, which is characterized by a cleft in the vertebral column, with a corresponding defect in the skin so that the meninges and spinal cord are exposed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"       \"Overview of the management of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13326731\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this topic review we will use the term &ldquo;encephalocele&rdquo; to describe lesions that include brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meninges. Some authors use the more general term &ldquo;cephalocele,&rdquo; and reserve the term &ldquo;encephalocele&rdquo; for lesions that include brain and &ldquo;meningocele&rdquo; for those that include only meninges [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Classification of encephalocele is based on the cause and anatomical location of the skull defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13326758\">",
"    <span class=\"h2\">",
"     Primary encephalocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary encephaloceles are congenital and present at birth. Primary encephaloceles are divided into three major types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sincipital (fronto-ethmoidal)",
"     </li>",
"     <li>",
"      Basal (trans-sphenoidal, spheno-ethmoidal, trans-ethmoidal, and spheno-orbital) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60761 \" href=\"UTD.htm?6/39/6769\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Occipital (",
"      <a class=\"graphic graphic_picture graphicRef69847 \" href=\"UTD.htm?25/23/25983\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74322 \" href=\"UTD.htm?19/18/19746\">",
"       image 2",
"      </a>",
"      ) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13326765\">",
"    <span class=\"h2\">",
"     Secondary encephalocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary encephaloceles are acquired and commonly due to trauma or a postsurgical defect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13323811\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An encephalocele is a type of malformation in which there are calvarial and dural defects with extracranial herniation of leptomeninges and sometimes of brain and cerebrospinal fluid (CSF).",
"   </p>",
"   <p>",
"    The central nervous system (CNS) appears as a plate of thickened ectoderm called the neural plate at the beginning of the third week of embryonic life. The lateral edges of the neural plate become elevated to form the neural folds and fuse to form the neural tube; the fusion begins in the cervical region and proceeds in both the rostral and caudal directions (",
"    <a class=\"graphic graphic_figure graphicRef81711 \" href=\"UTD.htm?20/24/20879\">",
"     figure 1",
"    </a>",
"    ). The rostral neuropore closes on the 25th day after conception, and the caudal neuropore closes two days later [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/6\">",
"     6",
"    </a>",
"    ]. Neural tube defects (NTDs) result from failure of the neural tube closure between 25 and 27 days after conception. The embryology of the neural tube is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=see_link&amp;anchor=H19221419#H19221419\">",
"     \"Pathogenesis and types of occult spinal dysraphism\", section on 'Normal cord development in humans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism causing primary (congenital) encephalocele is uncertain, although it involves defective closure of the anterior neural tube. Onset of the most severe lesions likely occurs prior to 26 days after conception; less severe lesions that primarily involve skull or meninges may occur later [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/7\">",
"     7",
"    </a>",
"    ]. Nasofrontal lesions are thought to result from defective separation of neural and surface ectoderm at the site of final closure of the rostral neuropore [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anterior encephaloceles (sincipital and basal) probably result from defective development of the prosencephalic neural crest tissue. This mechanism is suggested by the patency of the midline foramina which are open only transiently during normal craniofacial development [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    By contrast, the embryology of occipital encephaloceles suggests defective segmentation of the bones of the posterior cranium (supraoccipital, exoccipital, and basioccipital, and the posterior part of the parietal bones). These bones are not of neural crest origin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459373\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalocele is less common than other neural tube defects. Its prevalence has been estimated at 0.8 to 5 per 10,000 live births. In a report from the Metropolitan Atlanta Congenital Defects Program, 115 cases were identified from 701,458 live births during 1979 to 1998, a prevalence of 1.64 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/11\">",
"     11",
"    </a>",
"    ]. These cases included 91 liveborn infants, 18 stillbirths, and 6 elective terminations (likely an underestimate). Males and females were equally affected.",
"   </p>",
"   <p>",
"    Occipital encephaloceles are the most frequent type in North America and Western Europe, where about 85 percent of encephaloceles take this form [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/12\">",
"     12",
"    </a>",
"    ]. Their incidence ranges between 1 in 3000 to 1 in 10,000 live births. On the other hand, in Southeast Asia, parts of Russia, and central Africa, anterior encephaloceles are more frequent (1 in 3500 to 1 in 5000) than the occipital type. The true incidence of secondary encephaloceles is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459380\">",
"    <span class=\"h1\">",
"     INHERITANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated encephaloceles (ie, those that are not associated with other congenital anomalies) have generally not been shown to be familial. One exception is an autosomal dominant form of occipital encephalocele with incomplete penetrance that was reported in a Vietnamese family [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/13\">",
"     13",
"    </a>",
"    ]. Most of the affected individuals in this family were developmentally normal and had normal neurologic exams except for skin-covered occipital bulges. Therefore there was no evidence for any of the known genetic syndromes associated with encephaloceles in this family.",
"   </p>",
"   <p>",
"    Encephaloceles may be part of specific genetic syndromes if there are associated anomalies. The inheritance pattern for these syndromes is usually autosomal recessive, in which case the risk of recurrence in subsequent pregnancies is substantial. As an example, the risk of recurrence for an encephalocele with Meckel Gruber syndrome is 25 percent. (See",
"    <a class=\"local\" href=\"#H3459422\">",
"     'Associated anomalies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459415\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of encephalocele are variable depending upon the type (location) and severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sincipital (fronto-ethmoidal) encephaloceles may be occult lesions that are not noticeable or may present with marked craniofacial deformities (hypertelorism, telecanthus, orbital dystopia, or unilateral",
"      <span class=\"nowrap\">",
"       micro/anophthalmos).",
"      </span>",
"     </li>",
"     <li>",
"      Basal encephaloceles may or may not be apparent on external inspection, but there may be a broadened nasal bridge, hypertelorism, or other midfacial anomalies. Affected patients may present as a nasal or epipharyngeal mass, difficulty breathing, recurrent upper tract infections, nasal discharges, recurrent meningitis, or CSF leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occipital encephaloceles usually are obvious at the time of birth and many are diagnosed prenatally by ultrasonography. The neural tissue usually is covered by skin. Those of relatively large size may be associated with cranial nerve deficits, poor sucking and feeding, spasticity, blindness, seizures, or developmental delay. Neurologic deficits may progress after birth if hydrocephalus develops. Occipital encephalocele also may be associated with hind-brain anomaly (Chiari III malformation) in which herniating",
"      <span class=\"nowrap\">",
"       occipital/cerebellar",
"      </span>",
"      tissues distort the posterior fossa structures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74322 \" href=\"UTD.htm?19/18/19746\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26697?source=see_link\">",
"       \"Chiari malformations\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The protruding tissue of an encephalocele may consist of normal brain or fibrous atrophic gliotic tissue which has little or no function. In a nasofrontal encephalocele, most of the herniating mass consists of nonfunctional gliotic neural tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. On the other hand, occipital encephaloceles may include a variety of tissues. In a series of occipital encephaloceles, 32 percent contained cerebral tissue, 21 percent included cerebral and cerebellar tissue, 5 percent had cerebellar tissue, and 37 percent had glial nodules or dysplastic neural tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459422\">",
"    <span class=\"h1\">",
"     ASSOCIATED ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with encephalocele frequently have other malformations that may be part of recognized syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/11,17,18\">",
"     11,17,18",
"    </a>",
"    ]. In a series from Atlanta, at least one other major structural congenital defect was present in 17 of 83 (20 percent) of affected liveborn infants with encephalocele [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/11\">",
"     11",
"    </a>",
"    ]. This is a smaller proportion than in other series, due to exclusion of infants with chromosomal abnormalities, other major CNS lesions, and amniotic bands.",
"   </p>",
"   <p>",
"    The most common of the associated syndromes is Meckel Gruber syndrome (Meckel syndrome,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/249000\">",
"     MIM #249000",
"    </a>",
"    ), which includes occipital encephalocele, microcephaly, microphthalmia, polycystic kidneys, ambiguous genitalia, polydactyly, cleft lip and palate, and other malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, diagnosis, and treatment of nephronophthisis\", section on 'Meckel-Gruber syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other cerebral malformations are often associated with encephalocele. These include deformities of the tentorium, complete or partial agenesis of the corpus callosum, and myelomeningocele. Individuals with occipital encephaloceles frequently have hydrocephalus (30 to 50 percent), corpus callosal abnormalities (18 percent), and cerebral dysgenesis (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459429\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is apparent at birth in most of the occipital encephaloceles. Basal encephaloceles may present as a midline mass in the nose or may not be visible. An encephalocele may be mistaken for a nasal polyp if it is located within the nose or for a soft tissue tumor if it is covered with skin and anterior to the nose. These basal encephaloceles, either ethmoidal or sphenoidal, tend to present with meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3662326\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging should be performed to evaluate the intracranial components of the malformation and identify any associated brain or vascular anomalies. Computerized tomography (CT) scans are effective for detection of the extent of cranial defects. Magnetic resonance imaging (MRI) is effective for detection of the extent of neural herniation. It is especially useful for basal encephaloceles. Neuroimaging will also detect hydrocephalus, if present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5208824\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is accomplished by maternal screening of serum AFP levels and ultrasonography (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link&amp;anchor=H13#H13\">",
"     \"Prenatal screening and diagnosis of neural tube defects\", section on 'Screening'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    With ultrasonography, encephaloceles appear as a defect in the calvarium containing a cystic or solid mass with a gyral pattern that is contiguous with the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/21\">",
"     21",
"    </a>",
"    ]. Prenatal ultrasonography detects approximately 80 percent of encephaloceles. Fetal MRI has higher sensitivity for neural tube defects (NTDs), and can be used in cases where ultrasound results are not optimal or the diagnosis is uncertain, or to evaluate high-risk cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link&amp;anchor=H19#H19\">",
"     \"Prenatal screening and diagnosis of neural tube defects\", section on 'Prenatal diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3662296\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions which can appear similar to an encephalocele include neoplasms, congenital cysts, vascular malformations, and inflammatory lesions (",
"    <a class=\"graphic graphic_table graphicRef68011 \" href=\"UTD.htm?12/18/12588\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/1\">",
"     1",
"    </a>",
"    ]. The considerations vary depending on the location of the encephalocele. In general, encephaloceles are more likely to vary with respiration or crying. Imaging usually distinguishes the encephalocele by demonstrating the skull defect and communication with the intracranial space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459436\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When diagnosed prenatally, vaginal delivery may be safe if the lesion is relatively small. Large encephaloceles require cesarean section.",
"   </p>",
"   <p>",
"    Surgical treatment is appropriate in most cases unless the encephalocele is massive and there is severe microcephaly or other lethal anomalies. The procedure basically consists of removing the overlying sac and closing the defect including the dural defect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/22\">",
"     22",
"    </a>",
"    ]. In patients with basal encephaloceles or CSF leakage, prompt closure is important to reduce the risk of infection. Patients with hydrocephalus usually undergo ventriculo-peritoneal shunt placement prior to encephalocele repair to prevent postoperative CSF leaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459443\">",
"    <span class=\"h2\">",
"     Sincipital encephaloceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless there is CSF leakage, sincipital encephaloceles can be treated electively, ideally early in infancy to avoid deleterious effect of an enlarging encephalocele on craniofacial structures. Complete surgical repair includes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection of the herniated mass to be flush with the floor of the anterior cranial base",
"     </li>",
"     <li>",
"      Repair of the dural and cranium defect",
"     </li>",
"     <li>",
"      Correction of hypertelorism, when appropriate, with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reconstruction of the nasal elements",
"     </li>",
"     <li>",
"      Alignment of the horizontal ocular axis",
"     </li>",
"     <li>",
"      Cannulation of obstructed nasolacrimal ducts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459450\">",
"    <span class=\"h2\">",
"     Basal encephaloceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal encephaloceles require prompt surgical repair because of high prevalence of meningitis. Ideally, a craniofacial team usually consisting of neurosurgeons and plastic surgeons perform the repair. Reconstruction of the skull and dural defect is important to prevent meningitis. In the case of sphenoidal encephalocele, particular caution must be used during the repair because the third ventricle, hypothalamus, and optic pathway may be present in the encephalocele sac.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459457\">",
"    <span class=\"h2\">",
"     Occipital encephaloceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of patients with occipital encephalocele depends on the type of neural tissue that is protruding beyond the skull, as assessed by inspection during surgery. If the herniating mass consists of gliotic tissue, the mass is transected flush with the skull.",
"   </p>",
"   <p>",
"    If the mass contains normal brain, attempts should be made to preserve it. Several techniques have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expansion cranioplasties have been used to accommodate large amounts of herniated neural tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/23\">",
"       23",
"      </a>",
"      ]. One technique of expansion cranioplasty uses tantalum mesh to create an extracranial space for herniating tissues.",
"     </li>",
"     <li>",
"      Ventricular volume reduction is a two-stage technique in which the ventricles are artificially expanded, followed by intracranial transposition of the neural tissue. In the first stage, the dural sac is closed; this increases ventricular pressure to produce ventriculomegaly. After hydrocephalus develops, a ventriculoperitoneal shunt is placed, and then herniated brain is transpositioned into the new intracranial space as the ventricle contracts [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To preserve herniated occipital and cerebellar parenchyma, the tentorium is incised, creating infratentorial space, and the cerebral cortex retracted into this space [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3459464\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;For sincipital encephaloceles, craniofacial operations can usually be performed without intraoperative mortality or major complications. Most patients with nasofrontal encephaloceles have normal or near-normal intelligence and ultimately do well following the repair [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for patients with occipital encephalocele depends on the extent of herniated neural tissue in the sac and on the presence of associated anomalies. In one series, 17 percent of all patients with occipital encephaloceles had normal mental and physical development, and 83 percent were mentally",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physically impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/26\">",
"     26",
"    </a>",
"    ]. The subset with few anomalies and a small amount of neural herniation had a 53 percent chance of being physically and mentally normal, 28 percent chance of normal intelligence but physical impairment, and 19 percent chance of intellectual disability (mental retardation). In a separate series of 30 patients with occipital encephalocele, the mortality rate was 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/27\">",
"     27",
"    </a>",
"    ]. Factors related to prognosis include the size of the sac, the contents of the neural tissue, hydrocephalus, infection, and pathologies that accompany the condition.",
"   </p>",
"   <p>",
"    One series from a single center suggests that hydrocephalus and other intracranial abnormalities predict neurodevelopmental outcome, but the location (type) of the cephalocele does not [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/20\">",
"     20",
"    </a>",
"    ]. In a retrospective analysis of 85 cases of cephaloceles (68 encephaloceles and 17 meningoceles) 40 were frontal, 33 occipital, and 12 parietal. The most common associated intracranial abnormalities included hydrocephalus (27 percent), seizure disorder (20 percent), corpus callosal abnormalities (18 percent), and cerebral dysgenesis (13 percent). Cognitive development was normal in 48 percent of patients, and mildly, moderately, or severely delayed in 11, 16, and 25 percent of patients, respectively. On multivariate analysis, only hydrocephalus and the presence of intracranial abnormalities were significant predictors of developmental delay.",
"   </p>",
"   <p>",
"    Seizure disorders are present in about 20 percent of patients with congenital encephalocele [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/20\">",
"     20",
"    </a>",
"    ]. Rates may vary if patients with occult lesions are included; such patients may present with seizures, and small occult encephaloceles are discovered as a secondary finding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/28\">",
"     28",
"    </a>",
"    ]. In a literature review of 18 cases of encephaloceles with seizure, six (33 percent) were extra-temporal and 12 (67 percent) were temporal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3991/abstract/29\">",
"     29",
"    </a>",
"    ]. For the purpose of seizure control, all extra-temporal encephaloceles were managed with resection of the encephalocele. Among patients with temporal lobe encephaloceles, eight (67 percent) were treated with encephalocele resection and extended lobectomy, and four (33 percent) were treated only with resection of the encephalocele. The prognosis after surgery was generally good, and 17 patients were seizure-free postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5208347\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An encephalocele is a type of malformation in which there are calvarial and dural defects with extracranial herniation of leptomeninges and sometimes brain and cerebrospinal fluid (CSF). In populations where prenatal ultrasonography is routinely performed, about 80 percent of encephaloceles are detected prenatally. (See",
"      <a class=\"local\" href=\"#H13323811\">",
"       'Embryology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5208824\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated encephaloceles (ie, those that are not associated with other congenital anomalies) generally are not familial. Those with associated anomalies may be part of specific genetic syndromes such as Meckel Gruber syndrome, in which case the recurrence risk may be substantial. (See",
"      <a class=\"local\" href=\"#H3459380\">",
"       'Inheritance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3459422\">",
"       'Associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary encephaloceles are divided into sincipital, basal, and occipital types; the management and the prognosis vary among these types. (See",
"      <a class=\"local\" href=\"#H13326731\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sincipital encephaloceles range from occult lesions that are not noticeable to those with marked craniofacial deformities (hypertelorism, telecanthus, orbital dystopia, or unilateral",
"      <span class=\"nowrap\">",
"       micro/anophthalmos).",
"      </span>",
"      Unless there is CSF leakage, sincipital encephaloceles can be treated electively, ideally early in infancy. (See",
"      <a class=\"local\" href=\"#H3459443\">",
"       'Sincipital encephaloceles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basal encephaloceles may be trans-sphenoidal, spheno-ethmoidal, trans-ethmoidal, and spheno-orbital (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60761 \" href=\"UTD.htm?6/39/6769\">",
"       image 1",
"      </a>",
"      ), and may or may not be apparent on external inspection. They may present as a nasal or epipharyngeal mass, difficulty breathing, recurrent upper tract infections, nasal discharges, recurrent meningitis, or CSF leaks. They require prompt surgical repair because of high prevalence of meningitis. (See",
"      <a class=\"local\" href=\"#H3459450\">",
"       'Basal encephaloceles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occipital encephaloceles usually are obvious at the time of birth, and many are diagnosed prenatally by ultrasonography (",
"      <a class=\"graphic graphic_picture graphicRef69847 \" href=\"UTD.htm?25/23/25983\">",
"       picture 1",
"      </a>",
"      ). Those of relatively large size may be associated with cranial nerve deficits, poor sucking and feeding, spasticity, blindness, seizures, or developmental delay. Surgical management of patients with occipital encephaloceles depends on the type of neural tissue that is protruding beyond the skull. (See",
"      <a class=\"local\" href=\"#H3459457\">",
"       'Occipital encephaloceles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3460240\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Marvin Fishman and Dr. Grace Villarreal, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Towgifhi J. Cephaloceles. MedLink Neurology 1995 (updated 12/2010). Available at: file://www.medlink.com/medlinkcontent.asp (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/2\">",
"      Albert L Jr, DeMattia JA. Cocaine-induced encephalocele: case report and literature review. Neurosurgery 2011; 68:E263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/3\">",
"      Di Rocco F, Couloigner V, Dastoli P, et al. Treatment of anterior skull base defects by a transnasal endoscopic approach in children. J Neurosurg Pediatr 2010; 6:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/4\">",
"      Antonelli V, Cremonini AM, Campobassi A, et al. Traumatic encephalocele related to orbital roof fractures: report of six cases and literature review. Surg Neurol 2002; 57:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/5\">",
"      Ng JD, Payner TD, Holck DE, et al. Orbital trauma caused by bicycle hand brakes. Ophthal Plast Reconstr Surg 2004; 20:60.",
"     </a>",
"    </li>",
"    <li>",
"     Sadler TW. Langman's Medical Embryology, Lippincott Williams &amp; Wilkins, Philadelphia 1990. p.352.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/7\">",
"      Czeizel AE, Dud&aacute;s I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/8\">",
"      Hoving EW, Vermeij-Keers C. Frontoethmoidal encephaloceles, a study of their pathogenesis. Pediatr Neurosurg 1997; 27:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/9\">",
"      Francis-West PH, Robson L, Evans DJ. Craniofacial development: the tissue and molecular interactions that control development of the head. Adv Anat Embryol Cell Biol 2003; 169:III.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/10\">",
"      Tavella S, Bobola N. Expressing Hoxa2 across the entire endochondral skeleton alters the shape of the skeletal template in a spatially restricted fashion. Differentiation 2010; 79:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/11\">",
"      Siffel C, Wong LY, Olney RS, Correa A. Survival of infants diagnosed with encephalocele in Atlanta, 1979-98. Paediatr Perinat Epidemiol 2003; 17:40.",
"     </a>",
"    </li>",
"    <li>",
"     Jimenez DF, Barone CM. Encephaloceles, meningoceles, and dermal sinuses. In: Principles and Practice of Pediatric Neurosurgery, Albright AL, Pollack IF, Adelson PD (Eds), Thieme Medical Publishers, New York 1999. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/13\">",
"      Bassuk AG, McLone D, Bowman R, Kessler JA. Autosomal dominant occipital cephalocele. Neurology 2004; 62:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/14\">",
"      Richards CG. Frontoethmoidal meningoencephalocele: a common and severe congenital abnormality in South East Asia. Arch Dis Child 1992; 67:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/15\">",
"      David DJ. Cephaloceles: classification, pathology, and management--a review. J Craniofac Surg 1993; 4:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/16\">",
"      Simpson DA, David DJ, White J. Cephaloceles: treatment, outcome, and antenatal diagnosis. Neurosurgery 1984; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/17\">",
"      Cohen MM Jr, Lemire RJ. Syndromes with cephaloceles. Teratology 1982; 25:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/18\">",
"      Brown MS, Sheridan-Pereira M. Outlook for the child with a cephalocele. Pediatrics 1992; 90:914.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial hemorrhage: Neural tube formation and prosencephalic development. In: Neurology of the Newborn, 4th, WB Saunders, Philadelphia 2001. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/20\">",
"      Lo BW, Kulkarni AV, Rutka JT, et al. Clinical predictors of developmental outcome in patients with cephaloceles. J Neurosurg Pediatr 2008; 2:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/21\">",
"      Graham D, Johnson TR Jr, Winn K, Sanders RC. The role of sonography in the prenatal diagnosis and management of encephalocele. J Ultrasound Med 1982; 1:111.",
"     </a>",
"    </li>",
"    <li>",
"     Humphreys RP. Encephalocele and dermal sinuses. In: Pediatric Neurosurgery, 3rd, Cheek WR (Ed), WB Saunders, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/23\">",
"      Gallo AE Jr. Repair of giant occipital encephaloceles with microcephaly secondary to massive brain herniation. Childs Nerv Syst 1992; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/24\">",
"      Oi S, Saito M, Tamaki N, Matsumoto S. Ventricular volume reduction technique--a new surgical concept for the intracranial transposition of encephalocele. Neurosurgery 1994; 34:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/25\">",
"      Bozinov O, Tirakotai W, Sure U, Bertalanffy H. Surgical closure and reconstruction of a large occipital encephalocele without parenchymal excision. Childs Nerv Syst 2005; 21:144.",
"     </a>",
"    </li>",
"    <li>",
"     French BN. Midline fusion defects and defects of formation. In: Neurological Surgery, Youmans JR (Ed), WB Saunders, Philadelphia 1990. p.1164.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/27\">",
"      Kiymaz N, Yilmaz N, Demir I, Keskin S. Prognostic factors in patients with occipital encephalocele. Pediatr Neurosurg 2010; 46:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/28\">",
"      Aquilina K, Clarke DF, Wheless JW, Boop FA. Microencephaloceles: another dual pathology of intractable temporal lobe epilepsy in childhood. J Neurosurg Pediatr 2010; 5:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3991/abstract/29\">",
"      Faulkner HJ, Sandeman DR, Love S, et al. Epilepsy surgery for refractory epilepsy due to encephalocele: a case report and review of the literature. Epileptic Disord 2010; 12:160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6171 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3991=[""].join("\n");
var outline_f3_57_3991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5208347\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459289\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13326731\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13326758\">",
"      Primary encephalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13326765\">",
"      Secondary encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13323811\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459373\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459380\">",
"      INHERITANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459415\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459422\">",
"      ASSOCIATED ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459429\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3662326\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5208824\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3662296\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459436\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3459443\">",
"      Sincipital encephaloceles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3459450\">",
"      Basal encephaloceles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3459457\">",
"      Occipital encephaloceles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3459464\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5208347\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3460240\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6171\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6171|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/39/6769\" title=\"diagnostic image 1\">",
"      Trans-ethmoidal encephalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/18/19746\" title=\"diagnostic image 2\">",
"      MRI Chiari III malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6171|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/24/20879\" title=\"figure 1\">",
"      Cephalocaudad neurulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6171|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/23/25983\" title=\"picture 1\">",
"      Occipital encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6171|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/18/12588\" title=\"table 1\">",
"      Differential diagnosis of primary encephalocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11237?source=related_link\">",
"      Anencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26697?source=related_link\">",
"      Chiari malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=related_link\">",
"      Pathogenesis and types of occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3992="Overview of autoimmunity";
var content_f3_57_3992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of autoimmunity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3992/contributors\">",
"     Noel R Rose, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3992/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3992/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/57/3992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review provides an overview of autoimmunity. The discussion includes the common features underlying all of these disorders, the criteria for recognizing human disease, and the major new approaches to improve their treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmunity is an immune response directed against an antigen within the body of the host. The definition does not distinguish whether the response is innate or acquired and, if acquired, whether it is induced by a foreign or autochthonous antigen. It usually involves both T-cell and B-cell responses. It only requires that the immune response be directed to a self-antigen.",
"   </p>",
"   <p>",
"    Autoimmune disease is a pathologic condition caused by an acquired or adaptive autoimmune response. However, these definitions can be unclear since it is frequently difficult to assign causality when dealing with a human disease. It is useful, therefore, to consider the evidence of an autoimmune etiology of a human disease with three degrees of stringency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct evidence",
"     </li>",
"     <li>",
"      Indirect evidence",
"     </li>",
"     <li>",
"      Circumstantial evidence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CRITERIA FOR AUTOIMMUNE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;How do we determine whether autoimmunity is the cause of the disease rather than an accompanying feature or a consequence? The demonstration of autoantibodies is the first step in the diagnosis of these diseases, although the antibodies may not be the actual pathogens of the disorder. Naturally occurring autoantibodies are common in all immunologically competent people and may even rise nonspecifically during the course of disease or injury. Thus, the mere presence of autoantibodies does not necessarily establish a cause-and-effect relationship, since the autoantibodies may be the result, not the cause, of the disease process. We emphasize, however, that the presence of autoantibody responses has great value in diagnosing and prognosing many human diseases.",
"   </p>",
"   <p>",
"    Autoantibodies may be present many years before the diagnosis of diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, antiphospholipid syndrome, and type 1 diabetes mellitus. Combined with genetic information or family history, the presence of autoantibodies may be highly predictive of the later onset of an autoimmune disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Direct evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct evidence of causality implies that an autoimmune response can be shown to produce the disease. This usually involves transfer of autoantibody from a patient to a healthy recipient, either another human or an animal. A few instances of such transfers have been successfully performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One striking example is the reproduction of the disease pemphigus by injection of patient serum into a neonatal mouse [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/5\">",
"       5",
"      </a>",
"      ]. This procedure reproduces the essential pathologic features of the disease. Unfortunately, experimental successes of transfer of a human disease to an animal are relatively rare.",
"     </li>",
"     <li>",
"      Human-to-human transfer of autoantibody may also result from transplacental transmission of the disease. Examples of maternal-fetal transmission have been well-documented in cases of Graves' disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/6\">",
"       6",
"      </a>",
"      ], myasthenia gravis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/7\">",
"       7",
"      </a>",
"      ], the rash of neonatal lupus, and the complete heart block and other cardiac abnormalities in neonatal lupus associated with maternal lupus and Sj&ouml;gren's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/8\">",
"       8",
"      </a>",
"      ]. Most of the clinical manifestations in the offspring are temporary, because the autoantibody in these cases is provided through passive transfer of serum from the mother. An exception is the congenital heart block and other cardiac abnormalities of neonatal lupus, which are permanent and potentially life-threatening [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25162?source=see_link\">",
"       \"Pathogenesis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are situations in which the pathologic effects of antibody can be reproduced in vitro. The best examples are diseases of the blood, such as hemolytic anemia, leukopenia, or thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    .) Antiphospholipid antibodies, another example, are autoantibodies that may affect blood clotting in laboratory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important void in our studies of autoimmune disease is the lack of methods that directly show the pathogenic effects of T cells. Many attempts have, therefore, been made to adapt immunodeficient mice as &ldquo;living test tubes&rdquo; for the demonstration of autoimmune-induced pathology. Although few reports of such demonstrations are available, they have not, in general, been adopted into the mainstream of autoimmune research because of their poor reproducibility.",
"   </p>",
"   <p>",
"    Experiments showing the effects of cytotoxic lymphocytes against human tissue cells require that the cells be cultured in vitro without changes. Methods for tracking antigen-specific T cells in the body based on their ability to bind particular",
"    <span class=\"nowrap\">",
"     peptide/MHC",
"    </span>",
"    complexes are available and may provide valuable tools for direct demonstration of an autoimmune response in the future. Both class I and class II MHC tetramers are needed for these investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indirect evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second level of proof of causality relies upon indirect evidence. In human autoimmune disease, this requires the availability of an appropriate animal model in which the necessary transfer studies can be carried out. Different animal models are utilized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reproduction of disease in animals via immunization with the appropriate antigen",
"     </li>",
"     <li>",
"      Naturally occurring disease in animals that resembles its human counterpart",
"     </li>",
"     <li>",
"      Disease resulting from manipulation of the immune system",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Disease occurring after immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one disease model, the targeted disorder is reproduced by immunization with the appropriate antigen. Frequently, this antigen was previously identified in the human disease because it is a major target of autoantibody production. However, autoantibodies may not always be a reliable guide to identification of the pathogenic autoantigen that is recognized by T cells.",
"   </p>",
"   <p>",
"    Furthermore, extensive experimentation in many strains of genetically different animals is usually required before one can satisfactorily reproduce a human disease. The disease experimentally produced in the animal is rarely, if ever, a complete replica of the human disease. More often, it is an incomplete example of part of a more complex human disorder.",
"   </p>",
"   <p>",
"    A good example of an experimental model is autoimmune thyroiditis in the mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/12\">",
"     12",
"    </a>",
"    ]. Here, the experimental antigen, thyroglobulin, is a major target of autoantibody production in patients. In genetically susceptible strains of mice, immunization with thyroglobulin produces a pathological picture of chronic thyroiditis that closely resembles the human disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    .) Another useful example is myocarditis, which can be reproduced by immunization of susceptible mice with murine myosin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the most widely studied experimental models of autoimmune disease is experimental allergic encephalomyelitis (EAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/14\">",
"     14",
"    </a>",
"    ]. The demyelinating changes in the experimental disease bear many similarities to multiple sclerosis in humans. Three antigens can induce this disease in rodents: myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). The last produces axonal loss as well as demyelination and has a relapsing and remitting course similar to multiple sclerosis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/15\">",
"     15",
"    </a>",
"    ]. Manipulation of components of the immune system, such as the introduction of a T cell receptor for a disease-producing antigen into an otherwise disease resistant strain, has suggested that activation of antigen presenting dendritic cells is an important step in inducing autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/16\">",
"     16",
"    </a>",
"    ]. These animal models are valuable for studying pathogenesis but may not be useful indicators of etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Naturally occurring disease in animals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another type of disease model is derived from a naturally occurring disease in animals that resembles its human counterpart. For example, at least three diseases occur in particular genetic strains of mice that resemble many aspects of human SLE. They include the",
"    <span class=\"nowrap\">",
"     NZB/NZW",
"    </span>",
"    hybrid,",
"    <span class=\"nowrap\">",
"     MRL/lpr,",
"    </span>",
"    and BXSB [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/17\">",
"     17",
"    </a>",
"    ]. Many autoantibodies typical of lupus are found in these animals, and cell transfer experiments clearly establish these diseases as autoimmune in origin. However, it is not apparent what serves as the primary antigen for inducing the disease in these animals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another important spontaneous model is the NOD mouse, which develops a disease closely resembling type 1 (autoimmune) diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/18\">",
"     18",
"    </a>",
"    ]. These mice have been particularly useful for delineating the major genetic traits that increase susceptibility to the disease, some of which also appear to operate in human type 1 diabetes and other autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/19\">",
"     19",
"    </a>",
"    ]. The model has also been extremely valuable for testing new therapies for the human disease. As an example, the possibility of arresting or abrogating disease in susceptible children by intranasal administration of insulin or by injection of a glutamic acid decarboxylase (GAD) vaccine is undergoing clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Immune system manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third type of model is derived from experiments that manipulate the immune system of experimental animals, particularly mice. Models of inflammatory bowel disease have been described in animals in which particular cytokines such as interleukin (IL)-2 and IL-10 have been eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Mice deficient in programmed cell death-1 (PD-) immuno-inhibitory coreceptor develop autoimmune dilated cardiomyopathy with production of high titers of autoantibodies against cardiac troponin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/23\">",
"     23",
"    </a>",
"    ]. These knockout models teach us the importance of immunological homeostasis in preventing autoimmune disease.",
"   </p>",
"   <p>",
"    The most important genetic trait in determining susceptibility to autoimmune disease is the human major histocompatibility complex (MHC), HLA. Replacing the MHC of a mouse with a human susceptibility HLA haplotype can render the mouse susceptible to many experimentally induced autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/24\">",
"     24",
"    </a>",
"    ]. Moreover, simply inserting the susceptible HLA haplotype can sometimes induce spontaneous myocarditis in previously resistant mice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Circumstantial evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lowest level of proof, circumstantial evidence, is the one most commonly available to attribute an enigmatic human disease to autoimmunity. As usual, the first piece of suggestive evidence is the presence of autoantibodies.",
"   </p>",
"   <p>",
"    The hazards of using this kind of evidence as the basis for concluding that a disease is caused by autoimmunity have been previously described. Natural autoantibodies are very common and may even rise nonspecifically during the course of a disease process.",
"   </p>",
"   <p>",
"    A second kind of circumstantial evidence comes from the finding that autoimmune diseases tend to cluster, probably because they share some genetic susceptibility traits. As examples, a single individual will have more than one autoimmune disease, and members of the family share the same or even other autoimmune diseases. In addition, the association of one disease of unclear etiology with another of authentic autoimmune etiology strengthens the possibility that the former is also an autoimmune disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the autoimmune diseases show a particular bias to certain HLA haplotypes, usually the Class II category. Since the Class II MHC encode genes that are important in regulating the immune response, some rational connection may exist between the genetic constitution and susceptibility to a particular autoimmune disease.",
"   </p>",
"   <p>",
"    Furthermore, most but not all autoimmune diseases are more common in women than men. A sex bias, therefore, provides increased circumstantial evidence of an autoimmune etiology. Moreover, comparison of the sex-based differences in autoimmune diseases has provided new information on the differing pathogenic mechanisms involved in males and females [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the response of a disease to immunosuppressive treatment is often a valuable clinical indicator of autoimmune etiology. Establishing the etiologic agent of the disease may, therefore, seem less important if effective symptomatic treatment can be attained by immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDUCTIVE MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of autoimmunity is the defining characteristic of an autoimmune disease. An autoimmune response can be initiated by autologous or foreign antigens. Like all immune responses, autoimmunity is under strict genetic control of antigen recognition, cellular interactions, and eventual outcomes. In addition, non-genetic environmental agents may promote autoimmune responses. Infections, for example, can provide the requisite antigen by mimicking or altering of self antigens or by causing antigen &ldquo;spillage&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, infection can provide the inflammatory context that favors immune responses, activating through the innate immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, renewed attention has focused on Epstein-Barr virus as an instigating agent in SLE and other autoimmune conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENETIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite their diverse etiology, certain pathogenetic mechanisms are common to all autoimmune diseases. With few exceptions, they require the presence of self-reactive CD4 positive T lymphocytes. Diseases in which there is a chronic inflammatory response but no evidence of adaptive immunity in the form of self-reactive T cells are now referred to as autoinflammatory diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/32\">",
"     32",
"    </a>",
"    ]. Previously, self-reactive T-cells were believed to be deleted in the thymus and to be present only when they arise following somatic mutation, producing &ldquo;forbidden clones.&rdquo; The observation that autoimmune responses are not mono- or pauciclonal has demolished the original forbidden clone theory, but there are some striking examples in B cells of isotype (ie, immunoglobulin class or subclass) restriction that are still unexplained but may be related to receptor history (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thymic selection is critical for normal T-cell development and is dependent upon interaction with thymic stromal cells. The autoimmune regulator (AIRE) gene is an autosomal recessive gene that is responsible for intrathymic presentation of a number of autologous antigens. Mutations in AIRE gene cause several combinations of autoimmune endocrine diseases, such as autoimmune polyendocrinopathy Candidiasis ectodermal dystrophy (APECED), because the appropriate self antigens are not properly presented in the thymus.",
"   </p>",
"   <p>",
"    Although there is experimental evidence that deletion of self-reactive lymphocytes occurs in the thymus, this mechanism seems to be totally effective only for the most prominent systemically expressed antigens, such as those of the major blood groups and histocompatibility complex [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/34\">",
"     34",
"    </a>",
"    ]. By comparison, in the case of most other self-antigens, deletion of self-reactive T cells in the thymus is either lacking or incomplete. Fortunately, there are mechanisms in the periphery that retard the activation of those self-reactive T cells that escape deletion in the thymus.",
"   </p>",
"   <p>",
"    One well-studied mechanism is clonal anergy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/35\">",
"     35",
"    </a>",
"    ]. This term describes the unresponsive state of T cells that have encountered their specific antigen without costimulatory signals. Such cells may remain unresponsive for long periods of time. There is a risk that anergy can be terminated by an encounter with appropriate, non-specific, costimulatory signals from injured tissue.",
"   </p>",
"   <p>",
"    Another mechanism of peripheral self-tolerance involves immunological ignorance, that is, the lack of a productive encounter between the T cell and its corresponding",
"    <span class=\"nowrap\">",
"     peptide/MHC",
"    </span>",
"    complex on an antigen-presenting cell. Ignorance can be overcome by changes in antigen availability, such as presentation by an infecting microorganism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/36\">",
"     36",
"    </a>",
"    ]. These events can cause autoimmunity and can possibly give rise to autoimmune disease.",
"   </p>",
"   <p>",
"    A novel possibility is that autoimmunity may be triggered by the production of antibodies directed against peptides translated by anti-sense strand DNA, in which the sense strand translates an auto-antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/37\">",
"     37",
"    </a>",
"    ]. These antibodies, in turn, induce anti-idiotypic antibodies that may cross-react with the autoantigen.",
"   </p>",
"   <p>",
"    Finally, the autoimmune response is kept in check by active regulation, although eliminating regulatory cells generally cannot initiate autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/38\">",
"     38",
"    </a>",
"    ]. Among the major regulatory cells are a subset of T cells bearing the markers CD4, CD25, and forkhead box protein P3 (Fox P3) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/39\">",
"     39",
"    </a>",
"    ]. Two different subpopulations of CD4+ regulatory T cells (Tregs) can be distinguished. Naturally recurring Tregs exert their suppressive effects by cell-to-cell contact of membrane-bound molecules, such as CTLA-4. Induced Tregs, in contrast, are cell-contact-independent and operate mainly through soluble suppressive cytokines, such as IL-10 and TGF-&beta; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/40\">",
"     40",
"    </a>",
"    ]. Treg function and phenotype exhibit some plasticity, and cells with diminished suppressive capacity may be seen in some autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. A specialized population of T cells that also express the natural killer (NK) receptor (called NK-T cells) can also regulate autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/38,43\">",
"     38,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central tolerance is induced in B cells as well as T cells but, in general, is less efficient. Natural autoantibodies are a normal component of the innate immune response. Because of their cross-reactions and connectivity, they form a network that may be important in an initial protective immunity. The mechanism of central tolerance, important mainly in B cells, is receptor editing. It limits the random process of variable gene recombination during B cell development to exclude autoreactive B cell receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A heritable defect in the suppressive effects of CD4+ CD25+ Fox P3 regulatory T cells appears to be the mechanism underlying the rare lethal autoimmune human disease &ldquo;immune dysregulation, polyendocrinopathy, enteropathy, X-linked&rdquo; (IPEX syndrome, MIM 304790). Mutations in the forkhead box protein P3 (FOXP3) located on the X chromosome have been noted in most of the affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/44\">",
"     44",
"    </a>",
"    ]. In a mouse model, deficiency of FOXP3 results in an absence of CD4+ CD25+ T cells. In humans with IPEX, the number of regulatory T cells appears to be normal, but their ability to suppress autologous effector T cells is markedly impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether autoimmune disease will follow an autoimmune response depends upon both the quality of the immune response and the availability of the corresponding antigen. Antigens on the surface of circulating cells such as blood cells are readily available to circulating antibody, and, therefore, such cells may be damaged or eliminated by autoantibody acting with complement, killer T cells, or phagocytes. The receptors on cell surfaces such as the TSH receptor on the thyroid cell or on the acetylcholine receptor at neuromuscular junctions may also be directly attacked by autoantibody. This interaction may result in stimulating the receptor in Graves' disease or in blocking the neuromuscular transmission as observed in myasthenia gravis.",
"   </p>",
"   <p>",
"    In other diseases, autoantibodies are produced to particular enzymes. As an example, antibodies to the P450 enzymes are prominent in autoimmune hepatitis and primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. These enzymes are widely distributed in the body, and the question arises of why the diseases are organ-specific. Evidence suggests that the enzymes are accessible to antibodies or T cells primarily in reactivated locations.",
"   </p>",
"   <p>",
"    Many other autoimmune diseases are not due to the direct effects of autoantibody. Rather, they are associated with T-cell-mediated immune responses. Sometimes, cytotoxic T cells may be generated that can damage their respective target cell. In other cases, cytokines are produced that are harmful to surrounding tissue cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/48\">",
"     48",
"    </a>",
"    ]. Finally, T cells may activate macrophages, which can produce a great deal of tissue injury through their soluble products, including cytokines and reactive oxygen intermediates. A functionally significant polymorphism of a lymphocyte specific phosphatase known as the protein tyrosine phosphatase non-receptor 22 gene (PTPN22) has been linked to T cell hyperresponsiveness. Carriage of the 1858T variant of PTPN22 is associated with several autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, and type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-throughput genetic and genomic studies have also focused attention on innate mechanisms in autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/50\">",
"     50",
"    </a>",
"    ]. The innate immune system uses sets of molecules known as pattern-recognition receptors that have been selected through evolution to recognize molecular patterns found in microorganisms. Families of pattern-recognition receptors include the Toll-like receptors, the nucleotide oligomerization domain (NOD)-like receptors, and the NACHT leucine-rich-repeat proteins (NALPs) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both NALP1 and NALP3 comprise part of cytoplasmic complexes called inflammasomes that regulate the activation of caspase 1, which converts interleukins into their active forms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/53\">",
"     53",
"    </a>",
"    ]. Variants of NALP1 are associated with autoimmune disorders that cluster with vitiligo (eg, autoimmune thyroid disease, latent autoimmune diabetes mellitus in adults, rheumatoid arthritis, psoriasis, pernicious anemia, and Addison's disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/54\">",
"     54",
"    </a>",
"    ]. Mutant NALP3, also known as cryopyrin, is linked to three inflammatory disorders associated with autosomal dominant inheritance: the familial cold urticaria syndrome, the Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In human disease, it is frequently impossible to clearly separate the injury that is due to antibody-mediated from cell-mediated reactions. In general, however, the cell-mediated responses are associated with the Th1 subset of CD4+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/56\">",
"     56",
"    </a>",
"    ]. Antibody-mediated mechanisms in general associate with Th2 responses. Thus, sometimes an autoimmune disorder can benefit by a shift from a Th1 to a Th2 response. This approach is one of several new concepts for therapy.",
"   </p>",
"   <p>",
"    This original simplistic view of the",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    dichotomy is not easily applied to human disease in which both Th1 and Th2 responses are generally evident. In fact, some autoimmune diseases are actually down-regulated by administering interferon-gamma (IFN-g), the prototypic Th1 cytokine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/57\">",
"     57",
"    </a>",
"    ]. It is now evident that a third T cell subset producing IL-17 (termed Th17) plays a critical role in several autoimmune conditions. Interestingly, there is a reciprocal relationship between Th17 and Treg that may dictate the final outcome of an autoimmune reaction. Inflammatory cytokines TGF-g and IFN-g play central roles in setting the balance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3992/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3519079\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune disease is a pathologic condition caused by an adaptive autoimmune response, an immune response directed against an antigen within the body of the host, termed a self-antigen. The response may be induced by a foreign or self antigen. It usually involves a T-cell and B-cell response. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The demonstration of autoantibodies is usually the first step in the diagnosis of an autoimmune disease, although it is not sufficient. The antibodies may not be the actual pathogens. Naturally occurring autoantibodies are common in all immunologically competent people and may even rise nonspecifically during the course of disease or injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Direct evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct evidence of causality, the most stringent level of evidence for autoimmunity, implies that an autoimmune response can be shown to produce the disease. This usually involves transfer of autoantibody from a patient to a healthy recipient, either another human or an animal. Additionally, there are situations in which the pathologic effects of antibody can be reproduced in vitro. An important void in our studies of human autoimmune disease is the lack of methods that directly show the pathogenic effects of T cells by adoptive transfer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Direct evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second level of proof of causality relies upon indirect evidence. In human autoimmune disease, this requires the availability of an appropriate animal model in which the necessary transfer studies can be carried out. Different animal models are utilized, including reproduction of disease in animals via immunization with the appropriate antigen, naturally occurring disease in animals that resembles its human counterpart, and disease resulting from manipulation of the immune system. The most important genetic trait in determining susceptibility to autoimmune disease is the human major histocompatibility complex, HLA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Criteria for autoimmune disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Disease occurring after immunization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Naturally occurring disease in animals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Immune system manipulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lowest level of proof, circumstantial evidence, is the one most commonly available to attribute an enigmatic human disease to autoimmunity. Such evidence may include autoantibodies, clustering of diseases within an individual or family, bias to certain HLA haplotypes, a sex bias, and a response to immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Circumstantial evidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An autoimmune response can be initiated by autologous or foreign antigens. Like all immune responses, autoimmunity is under strict genetic control of antigen recognition, cellular interactions, and eventual outcomes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inductive mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of autoimmune disease depends upon an imbalance between pathogenic factors generated by autoreactive T cells and B cells and the regulatory factors that normally control the immune response. For example, the balance of activities between various effector T cells (Teff) and regulatory T cells (Treg) helps to determine whether an individual maintains normal self-tolerance or progresses to autoimmune disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenetic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diseases in which there is chronic inflammation but no evidence of autoreactive T cells or B cells, termed autoinflammatory diseases, are associated with the innate immune response. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenetic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/1\">",
"      Rose NR. Autoimmune diseases: tracing the shared threads. Hosp Pract (Minneap) 1997; 32:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/2\">",
"      Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/3\">",
"      Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/4\">",
"      Rose NR. Predictors of autoimmune disease: autoantibodies and beyond. Autoimmunity 2008; 41:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/5\">",
"      Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/6\">",
"      Burman KD, Baker JR Jr. Immune mechanisms in Graves' disease. Endocr Rev 1985; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     Drachman DB. How to recognize an antibody-mediated autoimmune disease: Criteria. In: Immunologic Mechanisms in Neurologic and Psychiatric Disease, Waksman BH (Ed), Raven, New York 1990. p.183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/8\">",
"      Reichlin M, Brucato A, Frank MB, et al. Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 1994; 37:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/9\">",
"      Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/10\">",
"      HARTMANN RC, CONLEY CL. Studies on the initiation of blood coagulation, III. The clotting properties of canine platelet-free plasma. J Clin Invest 1952; 31:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/11\">",
"      Nepom GT, Buckner JH, Novak EJ, et al. HLA class II tetramers: tools for direct analysis of antigen-specific CD4+ T cells. Arthritis Rheum 2002; 46:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/12\">",
"      Vali M, Rose NR, Caturegli P. Thyroglobulin as autoantigen: structure-function relationships. Rev Endocr Metab Disord 2000; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/13\">",
"      Rose NR, Hill SL. The pathogenesis of postinfectious myocarditis. Clin Immunol Immunopathol 1996; 80:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/14\">",
"      Swanborg RH. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 1995; 77:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/15\">",
"      Weissert R, Kuhle J, de Graaf KL, et al. High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes. J Immunol 2002; 169:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/16\">",
"      Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 2004; 113:990.",
"     </a>",
"    </li>",
"    <li>",
"     Theofilopoulos AN. Immunologic genes in mouse lupus models. In: The Molecular Pathology of Autoimmune Diseases, Bona CA, Siminovich KA, Zanetti M, Theofilopoulos AN (Eds), Harwood, Chur, Switzerland 1993. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/18\">",
"      Leiter EH, Prochazka M, Coleman DL. The non-obese diabetic (NOD) mouse. Am J Pathol 1987; 128:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/19\">",
"      Huber A, Menconi F, Corathers S, et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev 2008; 29:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/20\">",
"      Dunger DB, Todd JA. Prevention of type 1 diabetes: what next? Lancet 2008; 372:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/21\">",
"      Horak I, L&ouml;hler J, Ma A, Smith KA. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995; 148:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/22\">",
"      K&uuml;hn R, L&ouml;hler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/23\">",
"      Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/24\">",
"      Mangalam AK, Rajagopalan G, Taneja V, David CS. HLA class II transgenic mice mimic human inflammatory diseases. Adv Immunol 2008; 97:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/25\">",
"      Elliott JF, Liu J, Yuan ZN, et al. Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice. Proc Natl Acad Sci U S A 2003; 100:13447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/26\">",
"      Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/27\">",
"      Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/28\">",
"      Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/29\">",
"      Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008; 30:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/30\">",
"      Fairweather D, Frisancho-Kiss S, Rose NR. Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis. Rev Med Virol 2005; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/31\">",
"      James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/32\">",
"      Grateau G, Duru&ouml;z MT. Autoinflammatory conditions: when to suspect? How to treat? Best Pract Res Clin Rheumatol 2010; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/33\">",
"      Panigrahi AK, Goodman NG, Eisenberg RA, et al. RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes. J Exp Med 2008; 205:2985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/34\">",
"      Dighiero G, Rose NR. Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 1999; 20:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/35\">",
"      Nossal GJ. A purgative mastery. Nature 2001; 412:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/36\">",
"      Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/37\">",
"      Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/38\">",
"      King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/39\">",
"      Buckner JH, Ziegler SF. Functional analysis of FOXP3. Ann N Y Acad Sci 2008; 1143:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/40\">",
"      Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003; 171:6323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/41\">",
"      Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/42\">",
"      Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011; 17:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/43\">",
"      McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002; 168:5979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/44\">",
"      Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/45\">",
"      Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/46\">",
"      Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem 2008; 15:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/47\">",
"      Lleo A, Invernizzi P, Mackay IR, et al. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008; 14:3328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/48\">",
"      Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/49\">",
"      Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. Rheumatology (Oxford) 2007; 46:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/50\">",
"      Gregersen PK. Modern genetics, ancient defenses, and potential therapies. N Engl J Med 2007; 356:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/51\">",
"      Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/52\">",
"      Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/53\">",
"      Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/54\">",
"      Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/55\">",
"      Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     Emmi L, Romagnani S. Role of Th1 and Th2 cells in autoimmunity. In: The Autoimmune Diseases, Rose NR, Mackay IR (Eds), Academic Press, San Diego 2006. p.83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/57\">",
"      Afanasyeva M, Georgakopoulos D, Rose NR. Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun Rev 2004; 3:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3992/abstract/58\">",
"      Martinez GJ, Nurieva RI, Yang XO, Dong C. Regulation and function of proinflammatory TH17 cells. Ann N Y Acad Sci 2008; 1143:188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5579 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3992=[""].join("\n");
var outline_f3_57_3992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3519079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CRITERIA FOR AUTOIMMUNE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Direct evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indirect evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Disease occurring after immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Naturally occurring disease in animals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Immune system manipulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Circumstantial evidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDUCTIVE MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENETIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3519079\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25162?source=related_link\">",
"      Pathogenesis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3993="Extrahepatic portal vein obstruction (portal vein thrombosis)";
var content_f3_57_3993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extrahepatic portal vein obstruction (portal vein thrombosis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3993/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3993/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3993/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3993/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/57/3993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal venous pressure is determined by the product of portal venous flow and the resistance to outflow from the portal venous system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Portal pressure = Portal venous flow x portal venous outflow resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Portal hypertension is defined by a hepatic venous pressure gradient (HVPG) greater than 5 mmHg. It is usually caused by an increase in resistance in the portal-hepatic vascular bed due to obstruction to flow, which is related to cirrhosis in the vast majority of patients. However, a variety of disorders can cause portal hypertension in the absence of cirrhosis, a condition referred to as \"noncirrhotic portal hypertension\".",
"   </p>",
"   <p>",
"    Portal hypertension has been categorized as prehepatic, intrahepatic, or posthepatic based upon the site of obstruction to flow (",
"    <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"     table 1",
"    </a>",
"    ). The intrahepatic causes of portal hypertension have been further subdivided as presinusoidal, sinusoidal, or postsinusoidal based upon the location of obstruction to portal blood flow in the liver (",
"    <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"     table 1",
"    </a>",
"    ). However, the location of portal venous obstruction in most causes of intrahepatic portal hypertension is mixed, particularly in patients with advanced liver disease.",
"   </p>",
"   <p>",
"    As a general rule, the clinical consequences of portal hypertension are similar regardless of the cause or site of obstruction. However, several pathophysiologic changes are related to specific types and causes of portal hypertension, which may influence their clinical presentation and therapy.",
"   </p>",
"   <p>",
"    A number of conditions have been associated with presinusoidal portal hypertension (",
"    <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"     table 1",
"    </a>",
"    ), but they are far less common than sinusoidal causes in North America and many other industrialized countries. However, in some parts of the world, presinusoidal causes, such as schistosomiasis, are major causes of portal hypertension.",
"   </p>",
"   <p>",
"    The pathophysiologic considerations in presinusoidal portal hypertension will be reviewed here with the major focus on extrahepatic portal vein thrombosis. Other important causes of presinusoidal portal hypertension (including noncirrhotic portal fibrosis and schistosomiasis), sinusoidal, and postsinusoidal causes of noncirrhotic portal hypertension are discussed separately as are issues related to the management of portal hypertension in general (such as ascites and variceal bleeding). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=see_link\">",
"     \"Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presinusoidal portal hypertension is caused by obstruction to flow through the portal venous system in the extrahepatic portion of the portal vein (extrahepatic presinusoidal portal hypertension) or at the level of portal vein branches within the liver (intrahepatic presinusoidal portal hypertension).",
"   </p>",
"   <p>",
"    Clamping the portal vein in experimental animal models produces a reflex increase in splanchnic arteriolar tone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/1\">",
"     1",
"    </a>",
"    ]. This decreases flow into the portal vein, and tends to nullify the effects of increased portal venous resistance from the clamp. However, in animal models of chronic presinusoidal portal hypertension, there is a paradoxical decrease in splanchnic arteriolar tone causing increased portal flow, which compounds and perpetuates the portal hypertensive state and contributes to the hyperdynamic circulation associated with portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/2\">",
"     2",
"    </a>",
"    ]. Tumor necrosis factor-alpha may contribute to this response [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperdynamic circulation in the portal vein stenosis model is less prominent than that seen in cirrhosis, a setting in which increased production of nitric oxide also contributes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/4\">",
"     4",
"    </a>",
"    ]. The reasons for this difference are not well understood. While it has been hypothesized that impaired hepatic reticuloendothelial function allows bacteria and endotoxins to reach the systemic circulation and activate nitric oxide production, experimental models do not support a role of endotoxin in prehepatic portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/5\">",
"     5",
"    </a>",
"    ]. Rather than an endotoxin-induced increased in iNOS (the inducible form of NO synthetase), it is the constitutively expressed NO synthetase (eNOS) that is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of extrahepatic portal vein thrombosis is not well-defined. In one series, portal vein thrombosis was considered to be the primary cause in 47 of 602 (8 percent) adults and children diagnosed with portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/8\">",
"     8",
"    </a>",
"    ]. Another study identified portal vein thrombosis in 79 of 701 hospitalized patients with cirrhosis (11 percent) who underwent routine ultrasound screening [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/9\">",
"     9",
"    </a>",
"    ]. Of these, 34 (43 percent) were asymptomatic while 45 (57 percent) had associated symptoms including portal hypertensive bleeding, abdominal pain, and intestinal infarction (due to concomitant mesenteric vein involvement).",
"   </p>",
"   <p>",
"    Portal vein thrombosis occurs in a number of settings, with the causes varying with age (",
"    <a class=\"graphic graphic_table graphicRef73799 \" href=\"UTD.htm?29/34/30251\">",
"     table 2",
"    </a>",
"    ). In children, the most common is omphalitis, which causes thrombophlebitis of the umbilical vein, and ultimately the portal vein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Portal vein thrombosis or obstruction of the portal vein without thrombosis is less often due to congenital agenesis or malformation of the portal vein.",
"   </p>",
"   <p>",
"    In adults, approximately 25 percent of patients with portal vein thrombosis have underlying cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/12\">",
"     12",
"    </a>",
"    ]. In these patients, the presence of portal vein thrombosis should be considered when there is an otherwise unexplained deterioration in clinical status. The annual incidence of portal vein thrombosis among patients with cirrhosis is less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of portal vein thrombosis in patients with cirrhosis appears to correlate with the severity of underlying liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. Why cirrhosis increases the risk of portal vein thrombosis has not been well studied, but is probably related to stasis or retrograde flow through the portal vein. In addition, portal vein thrombosis may occur after the development of hepatocellular carcinoma, suggesting a possible hypercoagulable state or direct invasion of the portal vein by the tumor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67676 \" href=\"UTD.htm?2/53/2898\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variety of causes of portal vein thrombosis in adults without cirrhosis has been described (",
"    <a class=\"graphic graphic_table graphicRef73799 \" href=\"UTD.htm?29/34/30251\">",
"     table 2",
"    </a>",
"    ). In one series of 184 such adults, 34 percent reported a prior history of abdominal surgery, 14 percent had pancreaticobiliary disease, and 9 percent had alimentary tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/11\">",
"     11",
"    </a>",
"    ]. These conditions may have predisposed to portal vein thrombosis because of direct injury to the portal vein, stasis of portal vein blood flow, or hypercoagulability. In another series, a local risk factor (eg, acute pancreatitis) was observed in 21 percent of patients while a prothrombotic mutation was found in 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/14\">",
"     14",
"    </a>",
"    ]. In a meta-analysis, myeloproliferative neoplasms were identified in 32 percent of patients with portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No apparent cause for portal vein thrombosis is evident in more than 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/8,14,16\">",
"     8,14,16",
"    </a>",
"    ]. Many of these patients probably have an underlying hypercoagulable state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following hypercoagulable states have been identified in different studies comparing patients with portal vein thrombosis compared to various controls (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prothrombin gene mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/9,17,19-21\">",
"       9,17,19-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Protein C deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/18,21\">",
"       18,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Protein S deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antithrombin deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      MTFR gene mutation that raises homocysteine [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myeloproliferative disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/16,21,22\">",
"       16,21,22",
"      </a>",
"      ], in some cases diagnosed only by the presence of a JAK2 617F mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"       \"Overview of the myeloproliferative neoplasms\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased factor VIII levels [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative frequency of a hypercoagulable state in patients with portal vein thrombosis can be illustrated by observations in two series. In a case-control trial, mutations in factor V Leiden (13 versus 7.5 percent), the prothrombin gene (35 versus 2.5 percent), and the MTFR gene (44 versus 5 percent) were more frequent in 23 cirrhotic patients with portal vein thrombosis than in 40 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/17\">",
"     17",
"    </a>",
"    ]. Overall, a thrombophilic genotype was detected in 70 percent of patients.",
"   </p>",
"   <p>",
"    The second study compared 65 patients with extrahepatic portal vein thrombosis without overt neoplastic disease or cirrhosis with 500 patients with lower limb deep vein thrombosis (DVT) and 700 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/21\">",
"     21",
"    </a>",
"    ]. At least one thrombophilic abnormality was detected in 40 percent of patients with portal vein thrombosis or DVT compared with only 13 percent of controls. Portal vein thrombosis was associated with the prothrombin gene mutation and deficiencies of antithrombin, protein C, and protein S. Prothrombin gene mutations were more likely in those with portal vein thrombosis compared with those with DVT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients have more than one thrombophilic state [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/18,21,26\">",
"     18,21,26",
"    </a>",
"    ]. In a study of 92 patients with portal vein thrombosis, the prevalence of zero, one, two, three, or four simultaneous acquired and inherited risk factors was 16, 47, 24, 10, and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACUTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute portal vein thrombosis is usually clinically silent, and is often diagnosed during radiologic examination for other reasons (such as acute pancreatitis). These thrombi are presumed to be acute because they do not have the radiographic appearance of chronic portal vein thrombosis described in the next section and the thrombosis often resolves spontaneously within days to weeks (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78815 \" href=\"UTD.htm?10/39/10865\">",
"     image 2",
"    </a>",
"    ). However, it is possible that in some reports of spontaneous recanalization, portal vein thrombosis may have been overdiagnosed due to failure to opacify the portal system with contrast as a result of retrograde flow. Thus, a normal second study gives the false appearance of spontaneous resolution. In patients with cirrhosis, portal vein thrombosis may present with abdominal pain and gastrointestinal bleeding. However, patients with acute thrombosis are not always symptomatic, and thus the incidence of acute thrombosis may be greater than reflected by symptomatic cases.",
"   </p>",
"   <p>",
"    The risk of recurrence in patients with incidentally discovered acute portal vein thrombosis has not been well-studied. In our experience, recurrence is rare, especially when there is only a partial nonocclusive thrombus and the condition leading to portal vein thrombosis has been reversed.",
"   </p>",
"   <p>",
"    Septic pylephlebitis should be considered in patients with acute portal vein thrombosis who have high fevers and chills. The possibility of intestinal infarction should also be considered in patients with acute onset of abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic portal vein thrombosis develops in patients whose thrombosis does not spontaneously resolve. This may either produce a chronic noncavernous thrombosed portal vein (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61314 \" href=\"UTD.htm?18/27/18867\">",
"     image 3",
"    </a>",
"    ) or cavernous transformation of the portal vein. Cavernous transformation refers to the development of collateral blood vessels that bring blood in a hepatopetal manner from the region of obstruction. When seen in a transverse section, as on a CT scan, cavernous transformation gives the appearance of multiple caveolar orifices (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51167 \" href=\"UTD.htm?6/56/7042\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with presinusoidal portal hypertension frequently form varices [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/27\">",
"     27",
"    </a>",
"    ]. When only a segment of the portal venous bed is obstructed, varices develop only in areas that decompress the corresponding segment. As an example, segmental portal hypertension within the splenic vein (splenic vein thrombosis) is associated with the formation of isolated gastric varices in the fundus of the stomach (",
"    <a class=\"graphic graphic_picture graphicRef58644 \" href=\"UTD.htm?14/18/14639\">",
"     picture 1",
"    </a>",
"    ). On the other hand, patients with portal vein thrombosis commonly form varices in sites other than the esophagus and stomach (ectopic varices) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common clinical manifestation of chronic portal vein thrombosis is variceal hemorrhage, which occurs at least once in 50 to 70 percent of patients and at least twice in 30 percent. In contrast to variceal bleeding in patients with cirrhosis, the risks of developing liver failure, encephalopathy, and death are much lower in patients with portal vein thrombosis or other causes of extrahepatic portal vein obstruction without underlying cirrhosis.",
"   </p>",
"   <p>",
"    More than 85 to 90 percent of patients with chronic portal vein thrombosis have esophageal varices, while 30 to 40 percent have concomitant gastric varices [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In one report, for example, large varices (F2 to F3) with red signs were present in 58 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .) The portal pressure, as measured by splenic pulp pressure, was significantly higher than the wedged hepatic venous pressure in 70 percent of patients, suggesting that the portal vein thrombosis extended up to the porta hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of patients with chronic portal vein thrombosis have splenomegaly, which may be massive; 10 percent of these patients have additional findings associated with hypersplenism such as anemia, thrombocytopenia, and leukopenia. The mechanisms are not fully understood but are related to increased venous congestion and splenic arterial flow. The degree of splenomegaly in patients with presinusoidal portal hypertension is often greater than in those with cirrhosis and massive splenomegaly may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small amount of ascites is present in about 10 percent of patients, particularly after gastrointestinal bleeding in which massive fluid resuscitation can lead to acute dilutional hypoalbuminemia. Sinusoidal portal hypertension (portal pressure &gt;12 mmHg) is usually required for the formation of ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .) Thus, patients with only presinusoidal portal hypertension typically do not have significant ascites unless they develop acute dilutional hypoalbuminemia during fluid resuscitation for a variceal bleed or have associated cirrhosis. In contrast, ascites more readily forms in postsinusoidal portal hypertension, even in the absence of well-established cirrhosis.",
"   </p>",
"   <p>",
"    A number of factors contribute to the lesser likelihood of ascites formation in prehepatic portal hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The smaller size of the fenestrations in intestinal capillaries compared with the liver, which results in a higher transcapillary oncotic pressure gradient [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/30\">",
"       30",
"      </a>",
"      ]. Thus, any pressure-induced increase in filtration of water is offset by a concomitant increase in intravascular oncotic pressure from the concentrated unfiltered proteins left in the vascular compartment.",
"     </li>",
"     <li>",
"      The greater compliance of the gastric and intestinal interstitium compared with the hepatic interstitium, which permits more fluid to be accommodated in the interstitium before it spills in to the peritoneal cavity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The large capacity of intestinal lymphatics to accommodate increases in intestinal lymph production due to filtration of fluid in the intestinal capillaries.",
"     </li>",
"     <li>",
"      The ultrastructure of the layers of the intestine, which allows preferential passage of fluid filtered in the submucosal capillary network to the mucosal surface and then the lumen rather than to the serosal surface and the peritoneal cavity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice, which is present in approximately 5 percent of patients, is usually related to concomitant hepatobiliary disease. Peripheral stigmata of chronic liver disease, such as palmar erythema and spider telangiectasias, are typically absent unless there is concomitant cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Abnormal liver biochemical tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biochemical tests, such as the serum alanine aminotransferase, are usually normal or only slightly increased. Measures of hepatic synthetic functions are typically preserved with the exception of hypoalbuminemia, which can be seen after fluid resuscitation for gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .) Liver failure should not occur unless patients have concomitant cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pylephlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the thrombosed portal vein (pylephlebitis) should be considered in patients with fever and bacteremia or sepsis in addition to the clinical manifestations described above. Pylephlebitis is most commonly observed in patients who have an underlying intraabdominal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33254?source=see_link\">",
"     \"Pylephlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Liver histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the liver parenchyma is not directly involved in patients with portal vein thrombosis, one would expect it to appear grossly and histologically normal. However, approximately 25 percent of patients have gross morphologic abnormalities (primarily irregularity with some surface nodularity), and 50 percent have histologic abnormalities. The most common histologic findings are portal fibrosis and nonspecific inflammatory infiltrates, which appear to be more frequent in adults than children (70 versus 50 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/11\">",
"     11",
"    </a>",
"    ]. However, these data were acquired prior to the availability of specific tests for hepatitis C. As a result, some of these gross and histologic changes may have reflected occult viral infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few controlled data on which to base clinical decisions in patients with portal vein thrombosis. Thus, treatment should be determined by an individual patient's clinical circumstances, the pathophysiology involved, and the available expertise. A surgical approach can be considered for patients with correctable anatomic abnormalities causing extrahepatic portal vein obstruction, provided there is no cirrhosis.",
"   </p>",
"   <p>",
"    Patients in whom portal vein thrombosis is suspected should undergo radiologic testing to define the extent of the clot. Ultrasound with Doppler flow studies, CT scanning, and magnetic resonance angiography are often helpful in this setting. Venous phase angiography remains the gold-standard in patients in whom the diagnosis is strongly suspected, but the above studies are unrevealing.",
"   </p>",
"   <p>",
"    An upper endoscopy should be performed to establish whether varices are present. Most patients with portal vein thrombosis should undergo evaluation for a hypercoagulable state; as mentioned above, the prothrombin gene mutation is one of the abnormalities that have been associated with spontaneous portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several anecdotal reports have documented successful lysis of acute portal vein thrombosis using streptokinase or tissue plasminogen activator administered locally by a catheter passed via a transjugular transhepatic or percutaneous transhepatic route [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. However, the benefit of this approach is uncertain since the natural history of this condition is not well-defined. Thrombolysis may be a reasonable option in patients with occlusive thrombosis, in whom the age of the thrombus is well-defined and whose clot has likely arisen from a hypercoagulable state. Patients with an underlying hypercoagulable disorder may be less likely to spontaneously recanalize and be at increased risk for recurrent thrombosis.",
"   </p>",
"   <p>",
"    A 2009 guideline issued by the American Association for the Study of Liver Diseases recommends giving anticoagulation therapy for at least three months starting with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and shifting to oral anticoagulation as soon as the patient's condition has stabilized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/37\">",
"     37",
"    </a>",
"    ]. Anticoagulation should be continued long-term in patients with acute portal vein thrombosis who have a permanent thrombotic risk factor that is not correctable. In a series of 95 patients, anticoagulation restored patency of the portal vein in 39 percent of patients after a median of 234 days. Failure to recanalize the portal vein was independently associated with the presence of ascites or an occluded splenic vein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The period defining when portal vein thrombosis becomes chronic has not been established. However, it is reasonable to assume that a period exists between the acute and the chronic stages. In one report, recent portal vein thrombosis was defined by the presence of three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent abdominal pain",
"     </li>",
"     <li>",
"      No evidence of chronic portal hypertension (gastrointestinal bleeding, ascites, collateral portosystemic circulation or hypersplenism)",
"     </li>",
"     <li>",
"      Contrast-enhanced CT or duplex-Doppler ultrasound showing no porto-portal collaterals at the porta hepatis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recanalization of the portal vein has been observed in such patients following chronic anticoagulation. The above study, for example, included 33 patients with recent portal or mesenteric vein thrombosis due to a variety of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/38\">",
"     38",
"    </a>",
"    ]. Anticoagulant therapy was begun at diagnosis and continued for at least four months in 31 of the patients. Follow-up imaging studies (performed after a mean of 4.9 months) revealed recanalization in 25 of 29 patients (86 percent) including complete recanalization in 10 patients. Bleeding was observed in two patients (one from esophageal varices two years after the diagnosis, and one other from hemorrhage within an ovarian cyst 15 months after the diagnosis).",
"   </p>",
"   <p>",
"    Similar findings were made in a study of 38 patients with portal vein thrombosis of whom 27 were anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/39\">",
"     39",
"    </a>",
"    ]. Anticoagulation was associated with recanalization of the portal vein in about 40 percent of patients compared with none of the 11 patients who were not anticoagulated. Anticoagulation was begun within 30 days of the onset of symptoms.",
"   </p>",
"   <p>",
"    Although these studies were observational, they suggest that chronic anticoagulation is a reasonable option in a very select subset of patients who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do not have underlying liver disease",
"     </li>",
"     <li>",
"      Have an acute or subacute symptomatic presentation",
"     </li>",
"     <li>",
"      Do not have evidence of a recanalization already underway",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic portal vein thrombosis depends upon the stage of the disease and the patient's comorbidities.",
"   </p>",
"   <p>",
"    Patients should be screened for esophageal varices [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/37\">",
"     37",
"    </a>",
"    ]. Although there are no controlled data, it is reasonable to administer nonselective beta blockers to decrease the risk of variceal bleeding. The rationale for this approach is provided by extensive experience in patients with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute bleeding from esophageal or gastric varices should be managed in the same manner as variceal hemorrhage in cirrhotic individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .) Sclerotherapy and band ligation have been used to obliterate esophageal varices following initial control of bleeding, with long-term survival exceeding 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. There is no role for anticoagulation in patients who have already developed cavernous transformation.",
"   </p>",
"   <p>",
"    Additional definitive salvage therapy should be considered for patients who experience repeated hemorrhage despite adequate endoscopic treatment, have isolated varices in the gastric fundus, or have ectopic varices. Surgery is the \"gold-standard\" for the treatment of such patients since it permanently corrects the varices and is usually well-tolerated because liver function typically remains well-preserved.",
"   </p>",
"   <p>",
"    The choice of surgery depends upon the anatomy of obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenectomy is curative in patients with splenic vein thrombosis and bleeding gastric varices [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with diffuse thrombosis of the portal, mesenteric, and splenic veins, a shunt operation may not be possible. Such patients may benefit from a nonshunting operation, such as a modified Sugiura procedure in which the esophagus is transected while devascularizing the paraesophagogastric region [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients in whom the mesenteric vein is open, a mesocaval shunt combined with splenectomy and left gastric vein ligature can be performed. Some patients may have a large spontaneous splenorenal collateral, which must be tied off during the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transjugular intrahepatic portosystemic shunting (TIPS) has been shown to be technically feasible in some cases of extrahepatic portal vein thrombosis, such as patients without cavernous transformation in whom the thrombosed vein can be accessed, dilated, and stented, and it may be considered in selected symptomatic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. However, the ability to adequately decompress the portal vein when there is an additional obstruction lower in the portal venous system is unpredictable. In addition, although TIPS may be technically feasible in patients with cavernous transformation, it is unlikely to adequately decompress the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/47,50\">",
"     47,50",
"    </a>",
"    ]. When performed, it is advisable to perform a thorough assessment for hypercoagulable states and consider anticoagulation after the bleeding is controlled. In those with impending bowel ischemia due to portal vein thrombosis, the decision regarding the best approach to decompress the portal vein and preserve the bowel should be individualized based upon the patient's comorbidities and available expertise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of anticoagulation in patients with chronic portal vein thrombosis is unclear. Such patients are at risk for thrombosis but are also at increased risk for variceal bleeding. These issues were addressed in a retrospective study that included 136 adults with nonmalignant, noncirrhotic portal vein thrombosis of whom 84 received anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/51\">",
"     51",
"    </a>",
"    ]. The majority of patients (72 percent) had an identifiable cause for hypercoagulability, the most common of which were myeloproliferative disorders, antiphospholipid syndrome, and septic pylephlebitis. The portal vein thrombosis was considered to be old in 103 patients (76 percent) and recent in the others. Moderate-sized esophageal varices were present in 64 of the 133 patients (48 percent).",
"   </p>",
"   <p>",
"    During a median follow-up of 46 months, the incidence of gastrointestinal bleeding was 12.5 per 100 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/51\">",
"     51",
"    </a>",
"    ]. Bleeding was more likely in those with large varices. Anticoagulant therapy did not increase the risk or the severity of bleeding. The incidence of thrombotic events was 5.5 per 100 patient-years. An underlying prothrombotic state in the absence of anticoagulation was an independent predictor of thrombosis. Two non-anticoagulated patients died of bleeding and thrombosis, respectively. Whether anticoagulation was associated with recanalization of the portal vein, improvement in liver function or a lessening of portal hypertension was not addressed. These data suggest that the risk of thrombosis is comparable to the risk of bleeding. The authors concluded that the",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio favors anticoagulant treatment.",
"   </p>",
"   <p>",
"    However, the take-home message from this study is uncertain when considering its limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although 103 patients were felt to have old thrombosis, most presented with symptoms and signs of mesenteric venous ischemia, which is unusual in patients with chronic portal vein thrombosis. Such patients usually present with splenomegaly and bleeding.",
"     </li>",
"     <li>",
"      The nature of the anti-coagulation was variable, with little information on the degree of anticoagulation.",
"     </li>",
"     <li>",
"      Thirty-five percent of patients experienced at least one episode of bleeding, the most common of which was variceal bleeding.",
"     </li>",
"     <li>",
"      Anticoagulation did not decrease the risk of bleeding; it decreased the risk of additional thrombotic events in other circulatory beds.",
"     </li>",
"     <li>",
"      Because the study was retrospective, it is possible that patients selected for anticoagulation may have been at relatively low risk for bleeding.",
"     </li>",
"     <li>",
"      Patients with cirrhosis were excluded. Such patients may be at increased risk for morbidity and mortality should a bleeding event occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2009 guideline from the American Association for the Study of Liver Diseases recommends consideration of long-term anticoagulation in patients with chronic portal vein thrombosis without cirrhosis who have a permanent risk factor for venous thrombosis that cannot be corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3993/abstract/37\">",
"     37",
"    </a>",
"    ]. In patients with gastroesophageal varices, anticoagulation should not be initiated until adequate prophylaxis for variceal bleeding has been instituted.",
"   </p>",
"   <p>",
"    Thus, anticoagulation in patients with chronic portal vein thrombosis should be decided upon on a case by case basis weighing the risk of bleeding versus thrombosis and the patient's ability to survive a bleed versus a thrombotic event. It may be desirable in those at high risk for recurrent thrombosis based upon clinical history of laboratory studies. The risk may be excessive in those with a history of gastrointestinal variceal bleeding (particularly in those with cirrhosis) unless adequate prophylactic measures to prevent recurrent bleeding can be implemented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Portal hypertension has been categorized as prehepatic, intrahepatic, or posthepatic based upon the site of obstruction to flow (",
"      <a class=\"graphic graphic_table graphicRef76516 \" href=\"UTD.htm?7/14/7404\">",
"       table 1",
"      </a>",
"      ). The intrahepatic causes of portal hypertension have been further subdivided as presinusoidal, sinusoidal, or postsinusoidal based upon the location of obstruction to portal blood flow in the liver. However, the location of portal venous obstruction in most causes of intrahepatic portal hypertension is mixed, particularly in patients with advanced liver disease.",
"     </li>",
"     <li>",
"      The major clinical consequences of portal hypertension in general are the formation of gastroesophageal varices, ascites, and splenomegaly. However, in contrast to sinusoidal and postsinusoidal forms of portal hypertension, ascites is much less common in patients with presinusoidal portal hypertension. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Portal vein thrombosis occurs in a number of settings, with the causes varying with age (",
"      <a class=\"graphic graphic_table graphicRef73799 \" href=\"UTD.htm?29/34/30251\">",
"       table 2",
"      </a>",
"      ). In children, the most common is omphalitis, which causes thrombophlebitis of the umbilical vein, and ultimately the portal vein. In adults, approximately 25 percent of patients with portal vein thrombosis have underlying cirrhosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are few controlled data on which to base clinical decisions in patients with portal vein thrombosis. Thus, treatment should be determined by an individual patient's clinical circumstances, the pathophysiology involved, and the available expertise. Management may in part depend upon how recent the thrombosis is suspected to be. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/1\">",
"      Witte CL, Witte MH, Bair G, et al. Experimental study of hyperdynamic vs. stagnant mesenteric blood flow in portal hypertension. Ann Surg 1974; 179:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/2\">",
"      Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244:G52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/3\">",
"      Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/4\">",
"      Niederberger M, Gin&eacute;s P, Martin PY, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996; 24:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/5\">",
"      Chu CJ, Lee FY, Wang SS, et al. Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension. J Hepatol 1999; 30:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/6\">",
"      Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003; 125:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/7\">",
"      Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276:G1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/8\">",
"      Belli L, Romani F, Riolo F, et al. Thrombosis of portal vein in absence of hepatic disease. Surg Gynecol Obstet 1989; 169:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/9\">",
"      Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/10\">",
"      Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979; 48:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/11\">",
"      Kameda H, Yamazaki K, Imai F, et al. Obliterative portal venopathy: A comparative study of 184 cases of extrahepatic portal obstruction and 469 cases of idiopathic portal hypertension. J Gastroenterol Hepatol 1986; 1:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/12\">",
"      Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/13\">",
"      Orloff MJ, Orloff MS, Orloff SL, Girard B. Portal vein thrombosis in cirrhosis with variceal hemorrhage. J Gastrointest Surg 1997; 1:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/14\">",
"      Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/15\">",
"      Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120:4921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/16\">",
"      Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/17\">",
"      Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/18\">",
"      Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/19\">",
"      Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008; 99:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/20\">",
"      Chamouard P, Pencreach E, Maloisel F, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/21\">",
"      Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/22\">",
"      Hoekstra J, Bresser EL, Smalberg JH, et al. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost 2011; 9:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/23\">",
"      P'ng S, Carnley B, Baker R, et al. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. Clin Gastroenterol Hepatol 2008; 6:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/24\">",
"      Qi X, Yang Z, Bai M, et al. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 2011; 33:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/25\">",
"      Koshy A, Jeyakumari M. High FVIII level is associated with idiopathic portal vein thrombosis in South India. Am J Med 2007; 120:552.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/26\">",
"      Denninger MH, Cha&iuml;t Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/27\">",
"      Alam H, Kim D, Provido H, Kirkpatrick J. Portal vein thrombosis in the adult: surgical implications in an era of dynamic imaging. Am Surg 1997; 63:681.",
"     </a>",
"    </li>",
"    <li>",
"     Burroughs AK, Bosch J. Clinical manifestations and management of bleeding episodes in cirrhotics. In: Oxford Textbook of Hepatology, McIntyre N, Benhamou JP (Eds), Oxford Scientific, 1990. p.408.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/29\">",
"      Blendis LM, Banks DC, Ramboer C, Williams R. Spleen blood flow and splanchnic haemodynamics in blood dyscrasia and other splenomegalies. Clin Sci 1970; 38:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/30\">",
"      Richardson PD, Granger DN, Mailman D, Kvietys PR. Permeability characteristics of colonic capillaries. Am J Physiol 1980; 239:G300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/31\">",
"      Witte CL, Chung YC, Witte MH, et al. Observations on the origin of ascites from experimental extrahepatic portal congestion. Ann Surg 1969; 170:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/32\">",
"      COURTICE FC. Lecture II: Ascites: the role of the lymphatice in the accumulation of ascitic fluid. Med J Aust 1959; 46(2):945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/33\">",
"      Blum U, Haag K, R&ouml;ssle M, et al. Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis. Radiology 1995; 195:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/34\">",
"      Cherukuri R, Haskal ZJ, Naji A, Shaked A. Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: long-term follow-up. Transplantation 1998; 65:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/35\">",
"      H&auml;nig V, Stenzel G, R&ouml;ssle M. [Acute portal vein thrombosis in liver cirrhosis: successful recanalization with the use of a portosystemic shunt (TIPS)]. Rofo 1996; 165:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/36\">",
"      Mann O, Haag K, Hauenstein KH, et al. [Septic portal vein thrombosis. Its successful therapy by local fibrinolysis and a transjugular portasystemic stent-shunt (TIPS)]. Dtsch Med Wochenschr 1995; 120:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/37\">",
"      DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/38\">",
"      Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/39\">",
"      Turnes J, Garc&iacute;a-Pag&aacute;n JC, Gonz&aacute;lez M, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 2008; 6:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/40\">",
"      Zargar SA, Javid G, Khan BA, et al. Endoscopic ligation vs. sclerotherapy in adults with extrahepatic portal venous obstruction: a prospective randomized study. Gastrointest Endosc 2005; 61:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/41\">",
"      Spence RA, Johnston GW, Odling-Smee GW, Rodgers HW. Bleeding oesophageal varices with long term follow up. Arch Dis Child 1984; 59:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/42\">",
"      Karrer FM, Holland RM, Allshouse MJ, Lilly JR. Portal vein thrombosis: treatment of variceal hemorrhage by endoscopic variceal ligation. J Pediatr Surg 1994; 29:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/43\">",
"      Spaander MC, Darwish Murad S, van Buuren HR, et al. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc 2008; 67:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/44\">",
"      Simpson WG, Schwartz RW, Strodel WE. Splenic vein thrombosis. South Med J 1990; 83:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/45\">",
"      Gouge TH, Ranson JH. Esophageal transection and paraesophagogastric devascularization for bleeding esophageal varices. Am J Surg 1986; 151:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/46\">",
"      Borgonovo G, Costantini M, Grange D, et al. Comparison of a modified Sugiura procedure with portal systemic shunt for prevention of recurrent variceal bleeding in cirrhosis. Surgery 1996; 119:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/47\">",
"      Ganger DR, Klapman JB, McDonald V, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: review of indications and problems. Am J Gastroenterol 1999; 94:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/48\">",
"      Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/49\">",
"      Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011; 60:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/50\">",
"      Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology 1993; 186:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3993/abstract/51\">",
"      Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120:490.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3579 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3993=[""].join("\n");
var outline_f3_57_3993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACUTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Varices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ascites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Abnormal liver biochemical tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pylephlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Liver histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3579\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3579|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/53/2898\" title=\"diagnostic image 1\">",
"      Hepatoma in cirrhosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/39/10865\" title=\"diagnostic image 2\">",
"      Acute portal vein thrombus CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/27/18867\" title=\"diagnostic image 3\">",
"      Chronic PV thrombosis MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/56/7042\" title=\"diagnostic image 4\">",
"      Cavernous transformation PV CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3579|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14639\" title=\"picture 1\">",
"      Gastric varix Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3579|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/14/7404\" title=\"table 1\">",
"      Classification NCPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/34/30251\" title=\"table 2\">",
"      Causes portal vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=related_link\">",
"      Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33254?source=related_link\">",
"      Pylephlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3994="Evaluation and treatment of acute lung transplant rejection";
var content_f3_57_3994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and treatment of acute lung transplant rejection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3994/contributors\">",
"     John J Reilly, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3994/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/57/3994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/57/3994/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/57/3994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute allograft rejection is a significant problem in lung transplantation. Despite advances in induction and maintenance immunosuppression, more than a third of lung transplant recipients are treated for acute rejection in the first year after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Acute rejection is responsible for approximately 4 percent of deaths in the first 30 days following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, evaluation, and treatment of acute cellular lung transplant rejection and the role of routine monitoring for rejection will be reviewed here. The immunobiology of transplantation, induction and maintenance immunosuppression after lung transplantation, humoral rejection, and chronic lung transplant rejection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=see_link\">",
"     \"Induction immunosuppression following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link\">",
"     \"Maintenance immunosuppression following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5081209\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cellular rejection &ndash; Acute cellular rejection is the predominant type of acute lung transplant rejection and is mediated by T lymphocyte recognition of foreign major histocompatibility complexes (MHC), also known as human leukocyte antigens (HLA) in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Humoral rejection &ndash; Humoral rejection, which is less common than acute cellular rejection, is mediated by antibodies directed against donor HLA epitopes. These antibodies may have been present in the recipient at a low level prior to transplant or may develop afterwards. Generally, if HLA antibodies are identified in the potential recipient, the corresponding HLA antigens are avoided in a donor (co-called virtual cross-match).",
"     </li>",
"     <li>",
"      Hyperacute rejection is a form of humoral rejection that occurs in the first 24 hours following lung transplantation in recipients who have preformed anti-HLA antibodies.",
"     </li>",
"     <li>",
"      Chronic lung transplant rejection is manifest pathologically as dense fibrous scar tissue affecting the small airways. Clinically, chronic lung transplant rejection is known as bronchiolitis obliterans syndrome (BOS), which is defined as a progressive decline in forced expiratory volume in one second (FEV1). Less commonly, chronic vascular rejection with atherosclerosis in the pulmonary vasculature is also present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discussions of humoral lung transplant rejection, including hyperacute rejection, and chronic lung transplant rejection are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5081202\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our knowledge of the pathology of lung allograft rejection comes from both clinical and experimental observations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. The histopathologic manifestation of acute cellular rejection is a lymphocyte-predominant inflammatory response centered on blood vessels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airways, the mechanism of which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The International Society for Heart and Lung Transplantation (ISHLT) has developed a \"Working Formulation of the Standardization of the Nomenclature in the Diagnosis of Lung Rejection,\" which was revised in 2007 (",
"    <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. This schema classifies rejection according to the anatomic structures involved and the severity of the abnormality. The key histopathologic features of acute cellular rejection are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A vascular component consisting of perivascular mononuclear infiltrates that may extend to the subendothelium; this lymphocyte infiltration can spread to involve the alveolar walls in higher grades of rejection (",
"      <a class=\"graphic graphic_picture graphicRef63730 graphicRef75560 \" href=\"UTD.htm?34/50/35625\">",
"       picture 1A-B",
"      </a>",
"      ). The specific alloantigens responsible for this vasocentric inflammatory response remain undefined. The grades range from A0 (no rejection) to A4 (severe).",
"     </li>",
"     <li>",
"      An airway component with a lymphocytic response initially in the submucosa of bronchioles and with increasing severity extending through the basement membrane. Bronchiolar inflammation may occur either in isolation or simultaneously with vascular inflammation. Ulceration of the airway epithelium may occur in more advanced cases (",
"      <a class=\"graphic graphic_picture graphicRef77118 graphicRef52040 \" href=\"UTD.htm?36/15/37113\">",
"       picture 2A-B",
"      </a>",
"      ). The grades range from B0 (no rejection) to B2R (high grade, revised 2007 system).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional eosinophils may be present in the vascular and bronchiolar components of acute cellular rejection. The presence of dense eosinophilic hyaline fibrosis in airways and vessels remains the key histologic discriminator between acute and chronic rejection of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079680\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR ACUTE REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acute lung transplant rejection is greatest in the first few months after transplant and decreases with time. Several factors have been implicated as contributing to the development of acute cellular rejection. The potential factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA mismatching &ndash; An increasing degree of HLA mismatch between the donor and recipient increases the risk of acute cellular rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2\">",
"       2",
"      </a>",
"      ]. However, mismatch at certain HLA loci may be more important than at others.",
"     </li>",
"     <li>",
"      Genetic factors &ndash; Genetic variants in interleukin (IL)-10, multidrug resistance genotype, CCL4L chemokine, and toll-like receptor 4(TLR4) may influence the risk of acute rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/13-16\">",
"       13-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunosuppression regimen &ndash; In the International Society for Heart and Lung Transplantation (ISHLT) registry, the rate of acute rejection in the first year was highest among recipients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      based regimens and lowest among those on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      based regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/3\">",
"       3",
"      </a>",
"      ]. Induction therapy with an interleukin-2R antagonist was associated with a lower rate of acute rejection than other induction regimens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758265#H32758265\">",
"       \"Maintenance immunosuppression following lung transplantation\", section on 'Calcineurin inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=see_link&amp;anchor=H2536653#H2536653\">",
"       \"Induction immunosuppression following lung transplantation\", section on 'Induction agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Age &ndash; More rejection episodes were reported among recipients in the lowest age category (18 to 34 years) than in older age categories, although this data from the ISHLT registry was not adjusted for underlying disease or other potentially confounding factors [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin D deficiency &minus; In a cohort of 102 lung transplant recipients, episodes of acute cellular rejection were more frequent among those with deficiency (&lt;30",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      in 25-hydroxyvitamin D (25OHD) near the time of transplantation, than among those with normal 25OHD levels (incidence rate ratio 2.43, 95% CI 1.30 to 4.52) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellular rejection is most likely to occur in the first six months following lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Often, patients are asymptomatic, and the diagnosis is made from surveillance transbronchial biopsies. When present, symptoms are nonspecific and are shared by other common complications that occur during this period. They include low-grade fever, shortness of breath, and cough with or without sputum production (",
"    <a class=\"graphic graphic_table graphicRef54968 \" href=\"UTD.htm?5/0/5131\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1,20\">",
"     1,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During long-term follow-up of 120 lung transplant recipients, shortness of breath and cough were more common in those with clinically significant acute rejection (grade &ge;A2) than those without (grade A0 or A1) (",
"    <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"     table 1",
"    </a>",
"    ), but comparable in frequency to those with pulmonary infection. For predicting grade &gt;A2 rejection, the sensitivity and specificity were 68 and 50 percent for cough and 63 and 68 percent for shortness of breath, respectively. &nbsp;",
"   </p>",
"   <p>",
"    Lung examination may reveal clear lung fields, crackles, or decreased breath sounds when a pleural effusion is present as part of the acute rejection. High grade rejection may be associated with respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472881\">",
"    <span class=\"h1\">",
"     EVALUATION OF SYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When lung transplant recipients present with nonspecific respiratory symptoms, the differentiation between acute allograft rejection, airway stenosis, and infection requires a combination of pulmonary function testing, imaging, and bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/20\">",
"     20",
"    </a>",
"    ]. As acute rejection requires intensification of immunosuppression, which could be deleterious in the presence of opportunistic infection, a definitive diagnosis is highly desirable. Most patients will require a transbronchial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435910\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing in patients with suspected acute lung transplant rejection is generally nonspecific. As infection is in the differential diagnosis, microbiologic stains and cultures are obtained from peripheral blood, sputum, and bronchoalveolar lavage samples. Cytomegalovirus (CMV) viral load testing is performed on peripheral blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link&amp;anchor=H695016#H695016\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\", section on 'CMV replication assays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ImmuKnow assay is an FDA-approved test intended to estimate the net state of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The role of the ImmuKnow assay in monitoring immunosuppression in lung transplant recipients is not well-established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph is typically obtained to assess the cause of new onset of dyspnea or cough in lung transplant recipients. Its main role in this setting is to identify diseases other than acute rejection. In early episodes of rejection (within the first three months), the chest radiograph may demonstrate perihilar opacities and interstitial edema with or without a pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the sensitivity and specificity of the chest radiograph are low [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1\">",
"     1",
"    </a>",
"    ]. The chest film is unchanged in approximately 80 percent of later episodes of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) is typically obtained to assess the severity and distribution of the disease process or to guide the bronchoscopist in choosing sites for bronchoalveolar lavage or transbronchial biopsy. HRCT findings of acute lung transplant rejection include ground glass opacities, septal thickening, volume loss, and pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1\">",
"     1",
"    </a>",
"    ]. However, HRCT findings are neither sensitive nor specific and do not differentiate between infection and rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1,26\">",
"     1,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348992\">",
"    <span class=\"h2\">",
"     Pleural fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are common in the first two weeks following lung transplantation and do not require fluid analysis unless the effusion is large or the patient has signs of infection. When a new onset pleural effusion is identified after the first couple of weeks, ultrasound guided thoracentesis is usually performed to obtain fluid for analysis and culture. Among patients with a pleural effusion associated with acute cellular lung transplant rejection, the pleural fluid is typically lymphocytic, although this finding is not specific. Chylothorax, another cause of lymphocytic effusions following lung transplantation, can develop due to disruption of the thoracic duct or as a complication of lymphangioleiomyomatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32103?source=see_link&amp;anchor=H7#H7\">",
"     \"The pleura in lung transplantation\", section on 'Pleural effusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is typically obtained at routine follow-up visits following lung transplantation and if dyspnea develops or worsens. The typical pulmonary function test abnormality in acute cellular lung transplant rejection is airflow obstruction manifest by a decrease in forced expiratory volume in one second (FEV1) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/27\">",
"     27",
"    </a>",
"    ]. The sensitivity of a decrease in FEV1 for detecting acute rejection is approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2,20,27\">",
"     2,20,27",
"    </a>",
"    ]. Thus, stable pulmonary function as determined by spirometry does not exclude acute lung transplant rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/27\">",
"     27",
"    </a>",
"    ]. Among lung transplant recipients, respiratory infection is associated with a similar decrease in FEV1, so spirometry does not differentiate between these entities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/27\">",
"     27",
"    </a>",
"    ]. Bronchial stenosis is in the differential diagnosis of airflow limitation following lung transplantation.",
"   </p>",
"   <p>",
"    Limited data are available on changes in total lung capacity (TLC) and diffusing capacity (DLCO) in association with acute lung transplant rejection. Among heart-lung transplant recipients, acute rejection is associated with decreases in TLC and DLCO [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4322117\">",
"    <span class=\"h2\">",
"     Flexible bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients present with a clinical syndrome suggestive of rejection or infection, most centers perform bronchoscopy with bronchoalveolar lavage and transbronchial biopsy in an attempt to establish a specific diagnosis (",
"    <a class=\"graphic graphic_table graphicRef72570 \" href=\"UTD.htm?5/51/5947\">",
"     table 3",
"    </a>",
"    ). The techniques of bronchoalveolar lavage (BAL) and transbronchial biopsy (TBB) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H5040289#H5040289\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Transbronchial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common clinical practice is to sample multiple lobes and segments of a single lung allograft. In patients with focal radiographic abnormalities, BAL and biopsies are concentrated in the area of the radiologic abnormality. Samples are sent for cell counts, microbiologic stains and cultures, cytology, and histopathology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bronchoalveolar lavage",
"      </strong>",
"       During the first three months following lung transplantation, total BAL cell counts are elevated, and a neutrophilic alveolitis (eg, 25 to 50 percent neutrophils) is common [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/28\">",
"       28",
"      </a>",
"      ]. In contrast, acute cellular rejection is associated with a lymphocytic alveolitis (eg, 10 to 60 percent lymphocytes) with a decreased",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio. However, these findings are nonspecific and lymphocytic alveolitis is also seen in viral pneumonias and obliterative bronchiolitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/28\">",
"       28",
"      </a>",
"      ]. Data is conflicting, but the degree of BAL lymphocytosis does not correlate well with the histologic grade of rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Transbronchial biopsy",
"      </strong>",
"       When imaging studies suggest diffuse disease or are normal, transbronchial biopsies are typically obtained from the lower lobes; when disease is radiographically patchy, biopsies are obtained from diseased areas [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/30\">",
"       30",
"      </a>",
"      ]. Practices vary concerning the number of transbronchial biopsies obtained for adequate sampling. Animal studies suggest that three good transbronchial biopsies have a sensitivity of 92 percent in identifying moderate to severe rejection and five biopsies have a similar sensitivity in identifying mild rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/12,31\">",
"       12,31",
"      </a>",
"      ]. Most centers try to obtain 6 to 10 biopsies in order to achieve 5 \"adequate\" or \"good\" specimens. The sensitivity of transbronchial biopsy for diagnosing acute rejection is 61 to 94 percent and the specificity greater than 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The sensitivity for the diagnosis of cytomegalovirus pneumonia is approximately 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Generally, only one lung is biopsied in during a single bronchoscopy in heart-lung or bilateral lung recipients. The major exception to this practice is in patients who have received bilateral living-donor lobar transplants. In these patients, the lower lobes come from two different donors, and rejection is typically limited to one of the donor lobes and is rarely bilateral. As a result, living-donor recipients with no localizing signs or radiographic abnormalities may need to have both lower lobes biopsied [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/34\">",
"       34",
"      </a>",
"      ]. Fluoroscopy can be used to document the absence of pneumothorax on the first side before proceeding to biopsy the contralateral side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse events reported with flexible bronchoscopy in lung transplant recipients are infrequent and include transient hypoxemia (10 percent), bleeding greater than 100 mL (4 percent), postprocedure pneumonia (2 percent), pneumothorax (1 to 3 percent), and arrhythmia (1 to 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2,19,35,36\">",
"     2,19,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58704371\">",
"    <span class=\"h1\">",
"     MONITORING ASYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellular lung allograft rejection is a major risk factor for development of chronic rejection manifest by bronchiolitis obliterans and bronchiolitis obliterans syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, an important goal of monitoring for acute allograft rejection in asymptomatic patients is to reduce the likelihood of late complications by preemptive treatment of acute cellular rejection. The two main forms of monitoring are spirometry and transbronchial biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58704398\">",
"    <span class=\"h2\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many centers, including ours, utilize patient-administered, daily home spirometry to monitor lung allograft function. Other centers perform spirometry at the time of follow-up visits. Once postoperative function has stabilized the variation in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) is less than 5 percent. Spirometry has been reported to have a sensitivity of 60 percent in detecting rejection (grade &ge;A2) or infection among bilateral lung transplant recipients (",
"    <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. A decline of 10 percent in spirometric values that persists for more than two days has been reported to indicate either rejection or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In single lung transplant recipients, spirometry is less helpful as changes may reflect progression of the underlying disease in the native lung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58704405\">",
"    <span class=\"h2\">",
"     Surveillance bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surveillance bronchoscopy with transbronchial biopsy remains controversial, and the performance of routine surveillance transbronchial biopsies varies between lung transplant centers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/35,42-44\">",
"     35,42-44",
"    </a>",
"    ]. The technique of transbronchial biopsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H5040289#H5040289\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Transbronchial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for surveillance biopsy protocols is based upon studies that show a substantial prevalence of pathologic evidence of rejection in asymptomatic patients. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retrospective evidence that up to 25 percent of surveillance transbronchial biopsies demonstrate evidence of allograft rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/35,44\">",
"       35,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 121 surveillance bronchoscopies, acute rejection, grade 2 or higher, was noted in 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1770 bronchoscopies, lymphocytic bronchiolitis grade 1 or higher was noted in 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrospective analysis demonstrating that lymphocytic bronchiolitis (grade B acute rejection) (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 1",
"      </a>",
"      ) is a risk factor for subsequent development of bronchiolitis obliterans [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a survival benefit of surveillance biopsies has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/44\">",
"     44",
"    </a>",
"    ]. A single-center, randomized trial of 47 recipients did not demonstrate any clinical benefit from surveillance biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/36\">",
"     36",
"    </a>",
"    ]. A separate retrospective study found that the presence of lymphocytic bronchiolitis, but not vascular rejection on transbronchial biopsy correlated with reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/37\">",
"     37",
"    </a>",
"    ]. This observation raised the possibility that previous studies that failed to demonstrate a benefit to surveillance bronchoscopy were looking at the wrong pathologic feature (ie, acute vascular rejection rather than lymphocytic bronchiolitis). Further research is needed to determine whether early treatment of lymphocytic bronchiolitis based on surveillance bronchoscopy results reduces the risk of BOS and improves survival.",
"   </p>",
"   <p>",
"    In a 2004 study, approximately 69 percent of North American lung transplant centers performed surveillance transbronchial biopsies, although a wide variety of protocols was used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/42,45\">",
"     42,45",
"    </a>",
"    ]. A representative surveillance biopsy schedule is: 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/42\">",
"     42",
"    </a>",
"    ]. Reports in the literature suggest a much lower yield after 24 months, and most centers do not routinely perform biopsies after this point. Some centers perform BAL without transbronchial biopsy after the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/35\">",
"     35",
"    </a>",
"    ]. Other centers use the history of rejection in the first four months to determine the frequency of surveillance biopsies at 6 months and beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58704412\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest imaging studies, including high resolution computed tomography (HRCT), have a low sensitivity (as low as 35 percent) for acute lung transplant rejection and are not used for screening [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/1,26\">",
"     1,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute cellular rejection in lung transplant recipients is based on the presence of characteristic histopathologic changes on transbronchial lung biopsy specimens (",
"    <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"     table 1",
"    </a>",
"    ) and exclusion of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/12\">",
"     12",
"    </a>",
"    ]. Transbronchial lung biopsies need to be interpreted by a pathologist with experience in lung transplantation. When the patient undergoes biopsy at a site other than a transplant center, it is common practice to send the biopsy slides to the transplant center for review. (See",
"    <a class=\"local\" href=\"#H5081202\">",
"     'Pathology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4322117\">",
"     'Flexible bronchoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For symptomatic patients, additional support for a diagnosis of acute cellular rejection includes the absence of airway stenosis at the time of flexible bronchoscopy and confirmation of negative microbiologic assays, stains, and cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=see_link\">",
"     \"Airway complications after lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical assessment without transbronchial biopsy is frequently inaccurate, as noted in a study from an experienced center [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/46\">",
"     46",
"    </a>",
"    ] in which only a 54 percent concordance rate was found between the clinical impression and the final pathologic diagnosis. Transbronchial lung biopsies improve the yield for a specific diagnosis to approximately 70 percent. (See",
"    <a class=\"local\" href=\"#H4322117\">",
"     'Flexible bronchoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the transbronchial biopsy does not yield a specific diagnosis and the patient has progressive respiratory impairment, repeat transbronchial biopsy or a video-assisted thoracoscopic lung biopsy may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5080629\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acute cellular rejection includes humoral rejection, airway complications (eg, stenosis at the bronchial anastomosis, airway granulation tissue), chronic rejection (bronchiolitis obliterans syndrome), thromboembolism, infection, and recurrent primary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. These alternate diagnoses are typically excluded by studies such as viral load assays for cytomegalovirus, fiberoptic bronchoscopy to examine the airway, D-dimer assessment, extensive microbiologic stains and cultures of bronchoalveolar lavage specimens, and histopathologic examination of transbronchial biopsies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=see_link\">",
"     \"Airway complications after lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=see_link&amp;anchor=H5#H5\">",
"     \"Noninfectious complications following lung transplantation\", section on 'Recurrent primary disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=see_link\">",
"     \"Noninfectious complications following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features that suggest infection include the presence of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute inflammatory cells such as polymorphonuclear leukocytes in the bronchoalveolar lavage",
"     </li>",
"     <li>",
"      Predominantly alveolar inflammation rather than vascular or airway-centered inflammation on biopsy (see",
"      <a class=\"local\" href=\"#H5081202\">",
"       'Pathology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Viral inclusions on cytology or transbronchial biopsy",
"     </li>",
"     <li>",
"      The presence of infectious pathogens on special stains or culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection and acute rejection can also occur together, and it can be difficult or impossible to make the diagnosis of acute rejection in the presence of viral infection (most commonly cytomegalovirus infection) because of the lymphocytic infiltrate that accompanies such infections. In the presence of active cytomegalovirus (CMV) infection, the approach is to treat the infection and then repeat the biopsies to assess any contribution of rejection to the patient's clinical syndrome. The alternative of empirically treating possible acute cellular rejection by intensifying immunosuppression is avoided as it would impair clearance of the CMV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACUTE CELLULAR REJECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58704759\">",
"    <span class=\"h2\">",
"     Deciding when to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat patients with histologic evidence of acute cellular rejection is based upon the clinical features and the histopathologic severity of rejection (",
"    <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"     table 1",
"    </a>",
"    ). There is widespread agreement that moderate or severe rejection (grade A3, A4) should be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. The management of minimal or mild rejection (grade A1, A2) is more variable and often depends on the clinical setting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physician and patient preference and philosophy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunosuppression is usually not increased in patients who have surveillance biopsies showing minimal rejection (A1) but have no clinical signs or symptoms suggestive of rejection (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link\">",
"       \"Maintenance immunosuppression following lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Practices are variable concerning the management of mild rejection on surveillance biopsies (A2) but no clinical signs or symptoms of rejection (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 1",
"      </a>",
"      ). Some centers elect not to treat asymptomatic A2 rejection, but will perform repeat surveillance bronchoscopy with biopsies in three to eight weeks. Our practice is to initiate treatment for A2 rejection even in the absence of symptoms.",
"     </li>",
"     <li>",
"      Most centers, including ours, treat patients with histologic evidence of minimal or mild rejection and a clinical syndrome suggestive of rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For symptomatic patients or those with radiographic abnormalities, empiric antibiotics are often initiated while waiting for culture results (",
"    <a class=\"graphic graphic_figure graphicRef58770 \" href=\"UTD.htm?21/33/22035\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H604798#H604798\">",
"     \"Bacterial infections following lung transplantation\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     High-dose glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen for treating acute rejection has not been determined, so treatment choices are based on clinical experience. Typically, treatment is initiated with high dose parenteral glucocorticoids, such as intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (500 mg to 1 g intravenously per day) for three days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. This can be done as an inpatient or outpatient, depending on patient symptoms, co-morbidities and available clinical infrastructure.",
"   </p>",
"   <p>",
"    Symptomatic improvement usually occurs over 24 to 48 hours in patients with symptoms of rejection, and the physiologic abnormalities begin to improve in the same time frame and return to baseline over several weeks. In a series of 85 patients with symptomatic acute lung transplant rejection, 47 (55 percent) responded to a glucocorticoid pulse, while 38 (45 percent) did not [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/49\">",
"     49",
"    </a>",
"    ]. The strongest predictor of glucocorticoid response was an onset a shorter time after transplantation.",
"   </p>",
"   <p>",
"    After high dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , patients are transitioned to oral glucocorticoids (typically 0.5 to 1.",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). Although specific regimens vary, the typical practice is to taper back to the baseline glucocorticoid dose over a several week period.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    , which is sometimes used as a substitute for methylprednisolone, is avoided in the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Follow-up bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for follow-up after treatment of an episode of acute cellular rejection are not standardized. Centers that perform surveillance bronchoscopy to evaluate suspected acute rejection will also generally perform follow-up bronchoscopy. We typically perform follow-up bronchoscopy with bronchoalveolar lavage and transbronchial biopsies approximately four weeks after therapy (range of two to eight weeks).",
"   </p>",
"   <p>",
"    In a retrospective study of 242 bronchoscopies performed to assess response to treatment for acute rejection, a pathologic abnormality was noted in 62 percent. The clinical impression of whether the patient had responded to treatment was accurate in only one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/46\">",
"     46",
"    </a>",
"    ]. Decisions about therapy for persistent rejection seen on follow-up biopsies are typically made by criteria similar to those outlined above for the initial diagnosis. (See",
"    <a class=\"local\" href=\"#H58704405\">",
"     'Surveillance bronchoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Persistent or refractory acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for persistent or refractory acute rejection is not well-established. A number of approaches have been reported, but scientific data to support one over another are lacking. For persistent acute cellular rejection, our approach has been to treat a second time with intravenous glucocorticoids (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 0.5 to 1 gram IV per day) for three days. An alternative, for patients on a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    based regimen, is to switch the maintenance immunosuppressive agent from cyclosporine to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/2,50-52\">",
"     2,50-52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'High-dose glucocorticoids'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758265#H32758265\">",
"     \"Maintenance immunosuppression following lung transplantation\", section on 'Calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the subsequent biopsy shows a lower grade of rejection and the patient is getting better clinically, we often observe and repeat biopsies in three to four weeks. On the other hand, if evidence of rejection grade &ge;A2 persists after two courses of glucocorticoids, we typically add antibody therapy (eg, OKT3, ATGAM,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/42,53,54\">",
"     42,53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758321#H32758321\">",
"     \"Maintenance immunosuppression following lung transplantation\", section on 'mTOR inhibitors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    If rejection appears severe or if the response to antibody therapy is incomplete, we also administer extracorporeal photopheresis (ECP) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. ECP consists of infusion of ultraviolet-A irradiated autologous peripheral lymphocytes which have been collected by apheresis and incubated with 8-methoxypsoralen. The mechanism by which ECP decreases immune responses in transplant recipients are unclear, but may involve enhancement of the number of peripheral regulatory T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/56,59\">",
"     56,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Extracorporeal photochemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and total lymphoid irradiation have been used in the past for patients with recurrent rejection, but are rarely used now [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5082262\">",
"    <span class=\"h2\">",
"     Adjusting maintenance immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Re-evaluating and optimizing the maintenance immunosuppression regimen is appropriate in patients with recurrent acute or persistent rejection on follow-up biopsies. This may include assessing blood levels of the immunosuppressive agents and the patient&rsquo;s adherence to their immunosuppression regimen, as well as adjusting the regimen. The following potential changes depend on the individual patient&rsquo;s maintenance regimen and the preferences of the local transplant team:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changing the maintenance immunosuppression from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/51,52,63\">",
"       51,52,63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758265#H32758265\">",
"       \"Maintenance immunosuppression following lung transplantation\", section on 'Calcineurin inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Changing the maintenance immunosuppression from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      to a mycophenolic acid precursor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758293#H32758293\">",
"       \"Maintenance immunosuppression following lung transplantation\", section on 'Nucleotide blocking agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      to the maintenance regimen, if the time since lung transplantation is more than three months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758321#H32758321\">",
"       \"Maintenance immunosuppression following lung transplantation\", section on 'mTOR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been evaluated as an alternative therapy for acute lung transplant rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Eighteen patients with acute rejection that failed to improve following high-dose glucocorticoid and antilymphocyte globulin therapy were treated with aerosolized cyclosporine. Two patients were unable to tolerate treatment, but 14 had improvement in histologic rejection grade [",
"    <a class=\"abstract\" href=\"UTD.htm?3/57/3994/abstract/65\">",
"     65",
"    </a>",
"    ]. Aerosolized cyclosporine is not commercially available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link&amp;anchor=H32758370#H32758370\">",
"     \"Maintenance immunosuppression following lung transplantation\", section on 'Future directions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15475603\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15476345\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis of acute cellular rejection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cellular rejection is the predominant type of acute lung transplant rejection and is mediated by T lymphocytes directed against the donor major histocompatibility complexes (MHC), also known as human leukocyte antigens (HLA) in humans. (See",
"      <a class=\"local\" href=\"#H5081209\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of acute cellular rejection is greatest in the first few months after lung transplant and decreases with time. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute cellular rejection is a lymphocyte predominant inflammatory response. Vascular (",
"      <a class=\"graphic graphic_picture graphicRef63730 graphicRef75560 \" href=\"UTD.htm?34/50/35625\">",
"       picture 1A-B",
"      </a>",
"      ) and airway (",
"      <a class=\"graphic graphic_picture graphicRef77118 graphicRef52040 \" href=\"UTD.htm?36/15/37113\">",
"       picture 2A-B",
"      </a>",
"      ) components are described, either in isolation or simultaneously. The grading of acute cellular rejection is described in the table (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5081202\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may be asymptomatic or may have low-grade fever, shortness of breath, or cough with or without sputum production. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of patients with suspected acute rejection typically includes laboratory testing for evidence of infection, chest imaging, spirometry, and flexible bronchoscopy. During bronchoscopy, bronchoalveolar lavage and transbronchial biopsies (usually 6 to 10 biopsies to achieve at least 5 adequate samples) are obtained from areas of focal radiographic abnormality or from lower lobe subsegments. (See",
"      <a class=\"local\" href=\"#H472881\">",
"       'Evaluation of symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring of asymptomatic patients usually includes spirometry and surveillance bronchoscopy to enable early diagnosis and treatment of acute rejection, and thus hopefully reduce the risk of subsequent development of chronic",
"      <span class=\"nowrap\">",
"       rejection/bronchiolitis",
"      </span>",
"      obliterans syndrome. (See",
"      <a class=\"local\" href=\"#H58704371\">",
"       'Monitoring asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute lung transplant rejection is based on the presence of characteristic histopathologic changes on transbronchial lung biopsy specimens (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of acute cellular rejection occurring in the first 24 hours following lung transplantation includes primary lung graft dysfunction, anastomotic dehiscence, and fluid overload. In the weeks to months after transplant, the differential includes infection, airway complications (eg, stenosis at the bronchial anastomosis, airway granulation tissue), chronic rejection (bronchiolitis obliterans syndrome), thromboembolism, and recurrent primary disease. (See",
"      <a class=\"local\" href=\"#H5080629\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15476337\">",
"    <span class=\"h2\">",
"     Treatment of acute cellular rejection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to treat patients with histologic evidence of acute cellular lung allograft rejection is dependent upon the clinical setting and the severity of the rejection (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H58704759\">",
"       'Deciding when to treat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with moderate or severe rejection (grade A3, A4) without evidence of lung infection, we recommend treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We also suggest treating patients with mild rejection (A2) and symptomatic patients with minimal rejection (grade A1) after excluding lung infection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The usual treatment is intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (0.5 to 1 gram IV per day) for three days. After clinical response, patients are transitioned to oral glucocorticoids, typically 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"       /day,",
"      </span>",
"      which is tapered to the patient&rsquo;s baseline dose over several weeks. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'High-dose glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent acute rejection, we suggest a second treatment series with intravenous glucocorticoids (eg, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , 0.5 to 1 gram IV daily for three days) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative, for patients on a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      based regimen, is to switch the maintenance immunosuppressive agent from cyclosporine to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Persistent or refractory acute rejection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for follow-up bronchoscopy after treatment of an episode of acute cellular rejection are not standardized. We typically perform a follow-up bronchoscopy approximately four weeks after treatment (range of two to eight weeks). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If evidence of acute cellular rejection persists on follow-up biopsies after two courses of glucocorticoids, an alternate immunosuppressive agent such as OKT3, ATGAM, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      is usually administered. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Persistent or refractory acute rejection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=see_link&amp;anchor=H2536653#H2536653\">",
"       \"Induction immunosuppression following lung transplantation\", section on 'Induction agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The maintenance immunosuppression regimen is usually adjusted in patients with recurrent acute or persistent evidence of rejection on follow-up biopsies. Potential changes include substituting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5082262\">",
"       'Adjusting maintenance immunosuppression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link\">",
"       \"Maintenance immunosuppression following lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/1\">",
"      Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/2\">",
"      Martinu T, Pavlisko EN, Chen DF, Palmer SM. Acute allograft rejection: cellular and humoral processes. Clin Chest Med 2011; 32:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/3\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant 2011; 30:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/4\">",
"      Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/5\">",
"      Chakinala MM, Trulock EP. Acute allograft rejection after lung transplantation: diagnosis and therapy. Chest Surg Clin N Am 2003; 13:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/6\">",
"      Adoumie R, Serrick C, Giaid A, Shennib H. Early cellular events in the lung allograft. Ann Thorac Surg 1992; 54:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/7\">",
"      Bach FH, Sachs DH. Current concepts: immunology. Transplantation immunology. N Engl J Med 1987; 317:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/8\">",
"      Krensky AM, Weiss A, Crabtree G, et al. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/9\">",
"      Burton CM, Iversen M, Scheike T, et al. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 2008; 27:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/10\">",
"      Yousem, SA, Berry, GJ, Brunt, EM, et al. A working formulation of the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung rejection study group. J Heart Lung Transplant 1990; 9:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/11\">",
"      Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/12\">",
"      Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/13\">",
"      Girnita DM, Webber SA, Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med 2008; 28:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/14\">",
"      Zheng HX, Zeevi A, McCurry K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/15\">",
"      Colobran R, Casamitjana N, Roman A, et al. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun 2009; 10:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/16\">",
"      Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005; 171:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/17\">",
"      Lowery EM, Bemiss B, Cascino T, et al. Low vitamin D levels are associated with increased rejection and infections after lung transplantation. J Heart Lung Transplant 2012; 31:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/18\">",
"      Burton CM, Iversen M, Scheike T, et al. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008; 85:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/19\">",
"      Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002; 21:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/20\">",
"      De Vito Dabbs A, Hoffman LA, Iacono AT, et al. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation? Heart Lung 2004; 33:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/21\">",
"      Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009; 87:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/22\">",
"      Bhorade SM, Janata K, Vigneswaran WT, et al. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008; 27:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/23\">",
"      Shino MY, Weigt SS, Saggar R, et al. Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes. J Heart Lung Transplant 2012; 31:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/24\">",
"      Otulana BA, Higenbottam T, Scott J, et al. Lung function associated with histologically diagnosed acute lung rejection and pulmonary infection in heart-lung transplant patients. Am Rev Respir Dis 1990; 142:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/25\">",
"      Millet B, Higenbottam TW, Flower CD, et al. The radiographic appearances of infection and acute rejection of the lung after heart-lung transplantation. Am Rev Respir Dis 1989; 140:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/26\">",
"      Gotway MB, Dawn SK, Sellami D, et al. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology 2001; 221:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/27\">",
"      Van Muylem A, M&eacute;lot C, Antoine M, et al. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax 1997; 52:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/28\">",
"      Tiroke AH, Bewig B, Haverich A. Bronchoalveolar lavage in lung transplantation. State of the art. Clin Transplant 1999; 13:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/29\">",
"      Clelland C, Higenbottam T, Stewart S, et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis 1993; 147:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/30\">",
"      Hasegawa T, Iacono AT, Yousem SA. The anatomic distribution of acute cellular rejection in the allograft lung. Ann Thorac Surg 2000; 69:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/31\">",
"      Tazelaar HD, Nilsson FN, Rinaldi M, et al. The sensitivity of transbronchial biopsy for the diagnosis of acute lung rejection. J Thorac Cardiovasc Surg 1993; 105:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/32\">",
"      Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/33\">",
"      Faro A, Visner G. The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr Transplant 2004; 8:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/34\">",
"      Starnes VA, Barr ML, Cohen RG. Lobar transplantation. Indications, technique, and outcome. J Thorac Cardiovasc Surg 1994; 108:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/35\">",
"      McWilliams TJ, Williams TJ, Whitford HM, Snell GI. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant 2008; 27:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/36\">",
"      Valentine VG, Gupta MR, Weill D, et al. Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation. J Heart Lung Transplant 2009; 28:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/37\">",
"      Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/38\">",
"      Morlion B, Knoop C, Paiva M, Estenne M. Internet-based home monitoring of pulmonary function after lung transplantation. Am J Respir Crit Care Med 2002; 165:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/39\">",
"      Otulana BA, Higenbottam T, Ferrari L, et al. The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation. Chest 1990; 97:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/40\">",
"      Bj&oslash;rtuft O, Johansen B, Boe J, et al. Daily home spirometry facilitates early detection of rejection in single lung transplant recipients with emphysema. Eur Respir J 1993; 6:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/41\">",
"      Becker FS, Martinez FJ, Brunsting LA, et al. Limitations of spirometry in detecting rejection after single-lung transplantation. Am J Respir Crit Care Med 1994; 150:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/42\">",
"      Levine SM, Transplant/Immunology Network of the American College of Chest Physicians. A survey of clinical practice of lung transplantation in North America. Chest 2004; 125:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/43\">",
"      Glanville AR. Bronchoscopic monitoring after lung transplantation. Semin Respir Crit Care Med 2010; 31:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/44\">",
"      Sandrini A, Glanville AR. The controversial role of surveillance bronchoscopy after lung transplantation. Curr Opin Organ Transplant 2009; 14:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/45\">",
"      Dransfield MT, Garver RI, Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. J Heart Lung Transplant 2004; 23:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/46\">",
"      Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med 1995; 152:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/47\">",
"      Izbicki G, Bairey O, Shitrit D, et al. Increased thromboembolic events after lung transplantation. Chest 2006; 129:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/48\">",
"      Ahmad S, Shlobin OA, Nathan SD. Pulmonary complications of lung transplantation. Chest 2011; 139:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/49\">",
"      Fuehner T, Simon A, Dierich M, et al. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation. Respir Med 2009; 103:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/50\">",
"      Meiser BM, Uberfuhr P, Fuchs A, et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997; 16:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/51\">",
"      Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/52\">",
"      Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/53\">",
"      Shennib H, Massard G, Reynaud M, Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant 1994; 13:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/54\">",
"      Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 2007; 7:2802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/55\">",
"      Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/56\">",
"      Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/57\">",
"      Wise BV, King KE, Rook AH, Mogayzel PJ Jr. Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient. Prog Transplant 2003; 13:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/58\">",
"      Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002; 26:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/59\">",
"      Meloni F, Cascina A, Miserere S, et al. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc 2007; 39:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/60\">",
"      Cahill BC, O'Rourke MK, Strasburg KA, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/61\">",
"      Ross HJ, Gullestad L, Pak J, et al. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. J Heart Lung Transplant 1997; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/62\">",
"      Valentine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996; 109:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/63\">",
"      Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/64\">",
"      Keenan RJ, Zeevi A, Iacono AT, et al. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 1995; 118:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/57/3994/abstract/65\">",
"      Keenan RJ, Iacono A, Dauber JH, et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 1997; 113:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4655 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3994=[""].join("\n");
var outline_f3_57_3994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15475603\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5081209\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5081202\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5079680\">",
"      RISK FACTORS FOR ACUTE REJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472881\">",
"      EVALUATION OF SYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435910\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348992\">",
"      Pleural fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4322117\">",
"      Flexible bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58704371\">",
"      MONITORING ASYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58704398\">",
"      Spirometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58704405\">",
"      Surveillance bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58704412\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5080629\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT OF ACUTE CELLULAR REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58704759\">",
"      Deciding when to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      High-dose glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Follow-up bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Persistent or refractory acute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5082262\">",
"      Adjusting maintenance immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15475603\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15476345\">",
"      Evaluation and diagnosis of acute cellular rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15476337\">",
"      Treatment of acute cellular rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4655|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/33/22035\" title=\"figure 1\">",
"      Infection timeline SOT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4655|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/38/41573\" title=\"picture 1A\">",
"      Acute rejection vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/51/1845\" title=\"picture 1B\">",
"      Acute rejection vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/4/40005\" title=\"picture 2A\">",
"      Acute rejection airway I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/56/9093\" title=\"picture 2B\">",
"      Acute rejection airway II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4655|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/10/13484\" title=\"table 1\">",
"      Pulmonary allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/0/5131\" title=\"table 2\">",
"      Signs and symptoms of rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/51/5947\" title=\"table 3\">",
"      Specimens from bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/44/15042\" title=\"table 4\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=related_link\">",
"      Airway complications after lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=related_link\">",
"      Induction immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=related_link\">",
"      Maintenance immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=related_link\">",
"      Noninfectious complications following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32103?source=related_link\">",
"      The pleura in lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=related_link\">",
"      Treatment of acute graft-versus-host disease: Clinical trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_57_3995="Causes of intrinsic pediatric acute kidney injury";
var content_f3_57_3995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of intrinsic pediatric acute kidney injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tubular injury (acute tubular necrosis)",
"       </td>",
"       <td>",
"        Prolonged ischemia, nephrotoxins, hypotension, sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal vascular diseases",
"       </td>",
"       <td>",
"        Hemolytic uremic syndrome, vasculitides, thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial diseases",
"       </td>",
"       <td>",
"        Interstitial nephritis, infections, malignant infiltrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerulonephritides",
"       </td>",
"       <td>",
"        Post-infectious glomerulonephritis, rapidly progressive glomerulonephritis, Henoch-Sch&ouml;nlein purpura",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3995=[""].join("\n");
var outline_f3_57_3995=null;
var title_f3_57_3996="NCCN guidelines PAS request";
var content_f3_57_3996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCCN guidelines for responding to requests for hastened death",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Address the request explicitly. Seek clarification if the patient uses a euphemism for death or refers to it indirectly. An expressed wish for death to come soon does not imply a desire for a lethal prescription.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distinguish the difference between a patient wishing not to live in their current state, versus wishing to be killed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explore the reasons for the request, and for its timing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for psychological/psychiatric issues, particularly depression, anxiety, grief, psychosis and delirium. Psychiatric consultation may be warranted to rule out potentially reversible causes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask about important relationships to family or significant others. Address the role of medical caregivers, and consider referral to hospice, if appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss individual values and personal views of suffering.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reassess symptom control and clarify the care plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer to explain the dying process, including information about the natural history of the patient's disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss alternatives to physician-assisted suicide, including treatment withdrawal, enhanced palliation of symptoms, not eating or drinking if appropriate, and/or sedation for refractory symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Know the local legal status of hastened death. Physician-assisted suicide is legal in Oregon with specific guidelines; euthanasia is not legal in any state in the United States. Treatment withdrawal and aggressive symptom management (including sedation) are legal, and do not constitute physician-assisted suicide.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Many physicians are inexperienced or personally uncomfortable with the concept of discussing physician assisted suicide with patients. Consider consultation with an Ethics Committee, Palliative care service, or experienced colleagues.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3996=[""].join("\n");
var outline_f3_57_3996=null;
var title_f3_57_3997="Diagnostic pemphigoid testing";
var content_f3_57_3997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic pemphigoid testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Procedure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transport",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Histology (H&amp;E)",
"       </td>",
"       <td>",
"        Skin or mucous membrane",
"       </td>",
"       <td>",
"        Lesional or part lesional",
"       </td>",
"       <td>",
"        At least 4 mm punch biopsy*",
"        <br/>",
"        <ul>",
"         <li>",
"          Specimen should contain intact epidermis/epithelium, basement membrane zone, and upper dermis/subepithelium",
"         </li>",
"         <li>",
"          Avoid torsion and crushing to prevent separation artifact",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        In",
"        <strong>",
"         formalin",
"        </strong>",
"        to a dermatopathology laboratory",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Direct immunofluorescence",
"       </td>",
"       <td>",
"        Skin or mucous membrane",
"       </td>",
"       <td>",
"        Perilesional",
"        <br/>",
"        <ul>",
"         <li>",
"          For cutaneous lesions, an erythematous or urticarial area next to a blister from a proximal anatomical location&nbsp;is ideal",
"         </li>",
"         <li>",
"          For mucous membrane lesions, avoid areas of scarring; since perilesional tissue may be friable, normal-appearing epithelium may be obtained",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        At least 4 mm punch biopsy*",
"        <br/>",
"        <ul>",
"         <li>",
"          Specimen should contain intact epidermis/epithelium, basement membrane zone, and upper dermis/subepithelium",
"         </li>",
"         <li>",
"          Avoid torsion and crushing to prevent separation artifact",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        In",
"        <strong>",
"         Michel's or Zeus medium",
"        </strong>",
"        to an immunodermatology laboratory",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indirect immunofluorescence and ELISA",
"       </td>",
"       <td>",
"        Serum",
"       </td>",
"       <td>",
"        Peripheral blood",
"       </td>",
"       <td>",
"        At least 5 mL of blood by venipuncture in serum tube (red top, NO anticoagulant); separate serum from clot and send serum",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        In",
"        <strong>",
"         serum tube",
"        </strong>",
"        to an immunodermatology laboratory",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If questions about specimen site selection or acceptable specimen handling conditions, contact an immunodermatology laboratory",
"    <div class=\"footnotes\">",
"     H&amp;E: hematoxylin and eosin pathology stain; ELISA: enzyme-linked immunosorbent assay.",
"     <br>",
"      * An alternative to two biopsies, one each for H&amp;E and direct immunofluorescence, as indicated above, is to obtain&nbsp;one 5 or 6 mm punch biopsy&nbsp;or one deep shave biopsy specimen that contains both lesional and perilesional tissue. The specimen&nbsp;is split into two pieces with a scalpel. Care should be taken&nbsp;to avoid&nbsp;disrupting the epidermis&nbsp;or crushing&nbsp;the specimen during splitting. The lesional portion is placed in formalin for H&amp;E histology and the perilesional portion is placed&nbsp;in Michel's or Zeus transport medium for direct immunofluorescence.",
"      <br>",
"       &Delta; Some immunodermatology laboratories will accept tissue on saline-saturated gauze if it is&nbsp;transported to the laboratory within six hours (the sooner the better and to be received during working hours) and will also accept tissue specimens flash frozen in liquid nitrogen and transported on dry ice.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        The serum can be separated without a centrifuge by allowing whole blood to clot in a tube for 1/2 hour to 2 hours. The serum on top of the clotted blood is then carefully transferred into a serum tube with a disposable pipette and sent to an immunodermatology laboratory. Alternatively, some immunodermatology laboratories accept whole blood if it is transported to the laboratory promptly (within six hours).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3997=[""].join("\n");
var outline_f3_57_3997=null;
var title_f3_57_3998="Contents: Gynecologic procedures";
var content_f3_57_3998=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic procedures",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic procedures",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/38/20070\">",
"           Barrier contraception: Diaphragm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33048\">",
"           Cervical intraepithelial neoplasia: Procedures for cervical conization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/14/24808\">",
"           Colposcopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/54/24420\">",
"           Culdocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11433\">",
"           Donor insemination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/131\">",
"           Endometrial sampling procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/27/3512\">",
"           Etonogestrel contraceptive implant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44071\">",
"           Evaluation and management of lower genital tract trauma in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/37/24150\">",
"           Hysterosalpingography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/56/37770\">",
"           In vitro fertilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/25/20887\">",
"           Initial approach to the premenopausal woman with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34265\">",
"           Insertion and removal of an intrauterine contraceptive device",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30408\">",
"           Interventional radiology in management of gynecological disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/11/15546\">",
"           Intracytoplasmic sperm injection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36819\">",
"           Intrauterine fetal transfusion of platelets",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20499\">",
"           Pelvic examination under anesthesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/55/40823\">",
"           Saline infusion sonohysterography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42681\">",
"           The gynecologic history and pelvic examination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22147\">",
"           Vaginoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/63/28659\">",
"           Word catheter placement for treatment of Bartholin cysts and abscesses",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-1E8512E02F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_57_3998=[""].join("\n");
var outline_f3_57_3998=null;
var title_f3_57_3999="Posterior vitreous detachment";
var content_f3_57_3999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior vitreous detachment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A horseshoe retinal tear with bridging retinal vein is evident. Vitreous is attached to the anterior flap of this tear. The bridging retinal vessel increases the risk of developing a vitreous hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ryan SJ, Langmore SE, Hinton D, Ogden TE. The Retina, 3rd ed, Volume 3: Surgical Retina, Mosby-Year Book, Inc., St. Louis 2001. Copyright &copy; 2001 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_57_3999=[""].join("\n");
var outline_f3_57_3999=null;
